<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://ijpdd.org/lib/pkp/xml/oai2.xsl" ?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/
		http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
	<responseDate>2026-05-21T19:10:36Z</responseDate>
	<request metadataPrefix="oai_dc" verb="ListRecords">https://ijpdd.org/index.php/files/oai</request>
	<ListRecords>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/39</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/40</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/41</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/42</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/43</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/44</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/45</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/46</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/47</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/49</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/50</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/51</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/54</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/56</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:BR</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/57</identifier>
				<datestamp>2023-03-11T07:26:11Z</datestamp>
				<setSpec>files:BR</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/60</identifier>
				<datestamp>2023-08-18T08:33:33Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/63</identifier>
				<datestamp>2023-08-18T08:33:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/64</identifier>
				<datestamp>2023-08-18T08:33:39Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/65</identifier>
				<datestamp>2023-08-18T08:33:25Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/66</identifier>
				<datestamp>2023-08-18T08:33:45Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/69</identifier>
				<datestamp>2023-12-09T05:03:41Z</datestamp>
				<setSpec>files:cv</setSpec>
			</header>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/71</identifier>
				<datestamp>2026-01-24T05:54:54Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">An Innovative Sintering Technique in  Pharmaceutical Industry</dc:title>
	<dc:creator xml:lang="en">Gupta, Vishal</dc:creator>
	<dc:creator xml:lang="en"> Kumar, Sokindra</dc:creator>
	<dc:creator xml:lang="en">Agrawal, Rajesh</dc:creator>
	<dc:subject xml:lang="en">Pharmaceutical dosage form, Modified Release, Controlled Release,  Sustained Release, Tablets, Sintering Technique</dc:subject>
	<dc:description xml:lang="en">The pharmaceutical dosage form is the dosage form by which active pharmaceutical ingredients are supplied to the patient as a unite dose, to provide a pharmaceutical effect in the body with minimum undesirable side effects. The most common dosage forms are solid dosage form (tablets, capsules, powders and granules in sachet, etc.) due to their excellent physical and chemical stability, cost effectiveness and are easy of manufacturing. Solid dosage form contains a unit dose of one or more APIs with an inert excipient. The tablets are formulated by traditionally either compression methods (Direct/ Wet/ Dry granulation) or an innovative sintering method after compression. The sintering is expressed as the joining of adjacent particles in a mass of powder, or in tablets, by the heat application. Conventional sintering technique involves heating of compact mass at a temperature below the melting point of the available solid constituents in a controlled environment. The sintering technique has manifold advantages over traditional dry or wet granulation method like minimum quantity of drug polymer ratio, easy tailoring of drug release profile, cost effective, high mechanical strength and less disintegration time for the manufacturing of modified release dosage forms. Sintering concept not only improves mechanical strength of dosage form, but it also controls the release of medicament on over an extended time period.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-10-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/71</dc:identifier>
	<dc:identifier>10.62896/ijpdd.v1.i1.01</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/71/25</dc:relation>
	<dc:relation>10.62896/wzwzrv21</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/72</identifier>
				<datestamp>2026-01-24T05:55:37Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Antimicrobial Resistance in a Globalized World:  Current Challenges and Future Perspectives</dc:title>
	<dc:creator xml:lang="en">Moh Aijaz</dc:creator>
	<dc:creator xml:lang="en">Ahmad, Mumtaz</dc:creator>
	<dc:creator xml:lang="en"> Ansari, Mohamamd Anas</dc:creator>
	<dc:creator xml:lang="en">Ahmad, Shmmon</dc:creator>
	<dc:subject xml:lang="en">Antimicrobial Resistance, Antibiotic Resistance, Drug Resistance,  Antimicrobial Agents, Antibiotic Stewardship</dc:subject>
	<dc:description xml:lang="en">Antimicrobial resistance (AMR) is an escalating global health crisis with profound implications for public health, agriculture, and economies worldwide. This review paper critically examines the current challenges and future perspectives of AMR within the context of our interconnected and globalized world. The proliferation of antimicrobial agents in healthcare, agriculture, and livestock production has led to the emergence of resistant pathogens. We explore the multifaceted factors contributing to AMR, including overuse and misuse of antibiotics, inadequate surveillance, and the rapid dissemination of resistant genes through international travel and trade. The consequences of AMR are dire, as it threatens the efficacy of antibiotics, rendering common infections untreatable and undermining modern medicine&#039;s cornerstone. This paper emphasizes the urgent need for a global collaborative approach to combat AMR. Furthermore, we discuss innovative strategies such as developing new antibiotics, enhancing stewardship programs, and promoting responsible antibiotic use in healthcare and agriculture. Additionally, we highlight the importance of international policy coordination, data sharing, and awareness campaigns to address AMR comprehensively. In conclusion, this review underscores that AMR is a pressing global challenge exacerbated by our interconnected world. However, with concerted efforts and a multifaceted approach, there remains hope for curbing the spread of resistance and preserving the effectiveness of antimicrobials for current and future generations.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/72</dc:identifier>
	<dc:identifier>10.62896/1wkwt966</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/72/26</dc:relation>
	<dc:relation>10.62896/z3yd5331</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/73</identifier>
				<datestamp>2026-01-24T05:55:59Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A REVIEW ON FLOATING DRUG DELIVERY SYSTEM:  AN INVENTIVE APPROACH IN GASTRO-RETENTIVE  SYSTEM</dc:title>
	<dc:creator xml:lang="en">Biswas, Kush</dc:creator>
	<dc:creator xml:lang="en">Chaurasia, Veerendra</dc:creator>
	<dc:subject xml:lang="en">Floating drug delivery system</dc:subject>
	<dc:description xml:lang="en">The development of an oral controlled release formulation has an incredible impact on the drug delivery area especially for the drugs with a narrow absorption window but the limitation of this approach is insufficient retention of drug in the stomach. Controlled release gastro-retentive dosage forms reside in the gastric region for long duration and thus reduce drug waste and improves bioavailability. Several other advantages are patient compliance, reduced fluctuation in plasma level, decrease intake of dose, reduced drug accumulation with limiting local and systemic side effects. Of several approaches utilized such as swelling and expanding systems, polymeric bio adhesive systems, high-density systems, modified-shape systems; the floating drug delivery system (FDDS) is the most feasible one.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/73</dc:identifier>
	<dc:identifier>10.62896/9g2v9n06</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/73/27</dc:relation>
	<dc:relation>10.62896/keptz071</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/74</identifier>
				<datestamp>2026-01-24T05:56:24Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A REVIEW ON LIPOSOMAL GEL FOR ACNE  VULGARIS</dc:title>
	<dc:creator xml:lang="en">Biswas, Kush</dc:creator>
	<dc:subject xml:lang="en">liposomes, gel formation</dc:subject>
	<dc:description xml:lang="en">Many different basic sciences have established liposomes as a promising new drug delivery method. Liposomes are tiny spheres made of an aqueous core and one or more lipid-based outer shells that are organized in a bilayer pattern. The ability to encapsulate hydrophilic and lipophilic medications and shield them from deterioration makes liposomes acceptable better carriers. It can penetrate deeper into the skin and, as a result, provide higher absorption. It also has an affinity for the keratin of the horny layer of skin. When applied to the skin, liposomes may function as a local depot, a matrix for solubilizing poorly soluble medicines, and an enhancer of penetration while also reducing their negative effects. Topical liposome formulations have the potential to be less harmful and more effective than standard formulations. The extended and controlled release of the topical dose forms used in liposome gel formulations may increase efficacy and patient compliance while producing therapeutically superior effects compared to those of standard formulations.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/74</dc:identifier>
	<dc:identifier>10.62896/6kgg4b72</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/74/28</dc:relation>
	<dc:relation>10.62896/mcmqs970</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/75</identifier>
				<datestamp>2026-03-10T05:57:28Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Allergies to Infections: Understanding the  Spectrum of Conjunctivitis</dc:title>
	<dc:creator xml:lang="en">Ali , Sayad Ahad</dc:creator>
	<dc:creator xml:lang="en">Ali, Shadab</dc:creator>
	<dc:creator xml:lang="en">Jahan, Iram</dc:creator>
	<dc:creator xml:lang="en">Anshu</dc:creator>
	<dc:subject xml:lang="en">Watery discharge, Bacterial conjunctivitis, Conjunctiva</dc:subject>
	<dc:description xml:lang="en">Conjunctivitis is described as any inflammatory condition of the membrane that covers the exposed sclera and borders the eyelids. This is the most common cause of red eye. Conjunctiva inflammation is a symptom of many different disorders, collectively referred to as conjunctivitis. Inflammations can be hyper acute, acute, or chronic, and they can have noninfectious or infectious origins. Conjunctiva injection, sometimes referred to as red eye, is a typical presentation for a number of ocular diseases and may account for as much as 1% of primary care visits. When both of these symptoms are present, 59% of cases with serious eye conditions, such as keratitis and anterior uveitis, may be identified. Moderate photophobia and anisocoria were significantly associated with serious eye conditions. When detecting fungus in immunocompromised persons or those with chronic blepharitis, Sabouraud agar plates are advised. Anaerobic culture plates could also be helpful, especially for people who have had surgery or trauma in the past. Acute hemorrhagic conjunctivitis (AHC) is a highly infectious type of viral conjunctivitis. The symptoms include chemosis, subconjunctival hemorrhage, edema of the eyelids, dilated conjunctiva vessels, and a sensation of a foreign mass. Neisseria gonorrhea is often the cause of hyper acute conjunctivitis in sexually active adults and newborns. Ocular allergies can affect other parts of the eye, such as the cornea, eyelids, and conjunctiva. Leonardi et al. classified ocular allergy diseases into three primary groups according to the immune mechanism causing the ultimate clinical manifestation. Viral conjunctivitis patients experience burning, watery discharge, red eyes, irritation, light sensitivity and a sudden foreign body sensation. In addition to the previously stated symptoms, patients with bacterial conjunctivitis also experience mattering of the eyelids upon waking and mucopurulent discharge. General supportive therapy for conjunctivitis patients includes avoiding allergens (dust mites, pollens, and animals), using artificial tears, washing your hands properly, applying cold compresses, not scratching your eyes, and using a gentle cleaner to get rid of any debris or allergens</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/75</dc:identifier>
	<dc:identifier>10.62896/8e05g555</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/75/29</dc:relation>
	<dc:relation>10.62896/ckj3af85</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/76</identifier>
				<datestamp>2026-03-06T07:57:33Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A NOVEL ANTIBIOTIC TO TREAT BACTERIAL  CONJUNCTIVITIS – BESIFLOXACIN</dc:title>
	<dc:creator xml:lang="en">Sridivya, Chandragiri</dc:creator>
	<dc:creator xml:lang="en">Paturi, Gayathri</dc:creator>
	<dc:creator xml:lang="en">Gugulothu, Suryam</dc:creator>
	<dc:creator xml:lang="en">Rajitha E</dc:creator>
	<dc:creator xml:lang="en"> Jatoth, Manjula</dc:creator>
	<dc:creator xml:lang="en">Suram, Rajasree</dc:creator>
	<dc:creator xml:lang="en">Jatoth, Thabitha</dc:creator>
	<dc:creator xml:lang="en"> Ramisetty, Priyanka</dc:creator>
	<dc:subject xml:lang="en">Conjunctivitis, Besivance, Fluoroquinolones, Bacterial conjunctivitis,  Besifloxacin</dc:subject>
	<dc:description xml:lang="en">The prevalence of bacterial conjunctivitis, popularly known as pink eye, which is caused by a variety of aerobic and anaerobic bacteria, is unaffected by demographics. To avoid possibly irreversible eye damage, prompt empiric therapy with a wide-ranging anti-infective, including a surface fluoroquinolone, is essential. The growth in methicillin-resistant Staphylococcus samples to ocular illness as well as fluoroquinolone resistance patterns throughout persons with various ocular bacterial infections need the development of novel eye-specific medicines. Besifloxacin, a brand-new broad-spectrum fluoroquinolone medication, has been approved for the treatment of bacterial conjunctivitis. It is associated with a decreased rate of resistance development and inhibits DNA gyrase and topoisomerase IV with a distinctly balanced dual-targeting activity. The only bacterial populations that are exposed to besifloxacin are those in and around the eye because it is not available in other formulations. By deliberately avoiding direct besifloxacin interaction with bacteria because a consequence of widespread use, this lowers the risk that bacterial tolerance might develop.In vitro, besifloxacin shown equal or greater activity than other common topical antibiotics. In clinical trials, besifloxacin has frequently demonstrated efficacy and safety in treating individuals with bacterial conjunctivitis. Besifloxacin is considered safe, well tolerated, and has no known side effects.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/76</dc:identifier>
	<dc:identifier>10.62896/269mps08</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/76/30</dc:relation>
	<dc:relation>10.62896/qeeavm57</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/77</identifier>
				<datestamp>2026-01-24T05:56:46Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A REVIEW ON EMULGEL IN THE TREATMENT  TOPICAL APPLICATION</dc:title>
	<dc:creator xml:lang="en">Biswas, Kush</dc:creator>
	<dc:subject xml:lang="en">Emulgel, advantages and disadvantages, macro and micro emulsion</dc:subject>
	<dc:description xml:lang="en">The simplest and most straightforward method of delivering localised medications through the skin, ophthalmic, rectal, vaginal, and other routes is topical drug administration. Topical drug delivery methods are those in which a formulation containing an active medicinal ingredient is applied directly to the skin to produce the drug&#039;s localising action. Local dermatological problems can be effectively treated with focused medication delivery. Drugs applied to the skin for their local action include antiseptics, antifungal agents, skin emollients, and protectants. This route of drug administration has grown in popularity because it avoids first-pass effects, gastrointestinal irritation, and metabolic degradation associated with oral administration. Emulgel is an emulsion of either the water-in-oil or oil-in-water type that has been gelled by combining with a gelling agent. The fundamental benefit of the emulgel is that it is simple to create emulgel formulations for medications that are lipophilic. Most lipophilic medications cannot be directly synthesized as hydrogels due to solubility issues. Because of this, emulgel offers superior lipophilic drug stability and release than a straightforward hydrogel foundation.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/77</dc:identifier>
	<dc:identifier>10.62896/myfxq760</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/77/31</dc:relation>
	<dc:relation>10.62896/j71a8z78</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/78</identifier>
				<datestamp>2026-01-24T05:57:09Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Intermetatarsal Bursitis: A case report (With  Accompanying Images)</dc:title>
	<dc:creator xml:lang="en">Km. Bhumika</dc:creator>
	<dc:creator xml:lang="en">Mandal, Suraj</dc:creator>
	<dc:creator xml:lang="en">Km. Shiva</dc:creator>
	<dc:subject xml:lang="en">Metatarsalgia; Bursitis; Intermetatarsal; MRI.</dc:subject>
	<dc:description xml:lang="en">Bursae are normally empty areas that are not filled with synovial fluid when they are in their natural form. Bursae are also referred to as bursa sacs. Bursae are sac-like structures that are sometimes seen in the body&#039;s joints. When synovial fluid begins to collect in the bursa, this is a symptom that a mechanical or inflammatory response has taken place in the region. The reaction might have been caused by friction or inflammation. Patients who are afflicted with rheumatoid arthritis often struggle with issues related to their inter-capito-metatarsal bursopathies (RA). The most common symptom is known as metatarsalgia, and it is characterised as a feeling that there is a &quot;stone in the shoe.&quot; This condition may be very painful. It seems that the diagnosis is correct, at least according to the results of the magnetic resonance imaging and the ultrasound (MRI).</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2023-12-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/78</dc:identifier>
	<dc:identifier>10.62896/1s2bfd90</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 1, Vol. 1, 2023</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/78/32</dc:relation>
	<dc:relation>10.62896/017yky86</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/80</identifier>
				<datestamp>2026-01-24T06:03:22Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Fast-Dissolving Tablets for the Treatment of Acute and  Chronic Diseases</dc:title>
	<dc:creator xml:lang="en">Anjali Gupta</dc:creator>
	<dc:creator xml:lang="en">Akash Yadav</dc:creator>
	<dc:creator xml:lang="en">Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">Fast dissolving tablet, bioavailability, rapidly absorbed, rapid  disintegration, Innovative medication</dc:subject>
	<dc:description xml:lang="en">Oral dose forms that dissolve quickly in the mouth are known as fast-dissolving tablets (FDTs). The effects will be felt sooner, patient compliance will increase, and it will be more convenient than taking a medication. FDTs are also easier to make and store than traditional tablets. A multitude of distinct technologies are capable of manufacturing FDTs. A popular method involves spray-drying the pharmacological ingredient into a thin film, which is then coated onto a carrier medium. Creating a solid dispersion of the medicinal component in a carrier material can also be done by the use of a technique called melt extrusion, which is another method. Drugs, including small compounds and biologics, can be formed into FDTs. FDTs are useful in treating a wide range of therapeutic indications, including the treatment of pain, the avoidance of migraines, and disorders related to the respiratory system. Patients who have trouble swallowing regular pills, such as younger children, the elderly, and those with dysphagia, may find these more manageable. Overall, FDTs have several benefits that traditional tablets lack. They work quickly in the body, boost patients&#039; adherence, and are simple to produce and keep on hand. Various medications can be effectively delivered with the use of FDTs.&amp;nbsp;</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-01-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/80</dc:identifier>
	<dc:identifier>10.62896/7yedfn45</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 2, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/80/33</dc:relation>
	<dc:relation>10.62896/tpa29n20</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/81</identifier>
				<datestamp>2026-03-10T06:09:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Exploring Innovative Approaches in Gastroretentive Drug Delivery Systems</dc:title>
	<dc:creator xml:lang="en">Mohini Rithoriya</dc:creator>
	<dc:creator xml:lang="en">Dr. Akash Yadav</dc:creator>
	<dc:creator xml:lang="en">Dr. Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">gastroretentive drug delivery system, mucoadhesive,  bioavailability, polymer, floating drug delivery system, effervescent.</dc:subject>
	<dc:description xml:lang="en">Gastroretentive drug delivery systems have emerged as a potential solution to enhance the bioavailability and efficacy of various pharmaceutical compounds. This review systematically evaluates the advantages and limitations of gastroretentive systems in drug delivery. The primary objective is to comprehensively analyze their mechanisms, formulationstrategies, and potential applications, focusing on their ability to prolong gastric residence time and improve drug absorption. Advantages of gastroretentive drug delivery systems include their capability to prolong drug release, maintain therapeutic concentrations, and reduce dosing frequency. This extended gastric residence time presents a viable approach for drugs with a narrow absorption window or those targeting specific regions of the gastrointestinal tract. Furthermore, these systems have the potential to improve patient compliance and, in turn, treatment outcomes. However, the review also highlights several challenges associated with gastroretentive systems. Variability in gastric emptying, potential gastrointestinal side effects,risk of local irritation, and complex formulation and manufacturing processes pose significantlimitations. Moreover, regulatory concerns and the potential risk of device dislodgement or aspiration require careful consideration.This review consolidates the current understanding of gastroretentive drug delivery systems, emphasizing the need for further research to address these limitations. Future advancements in formulation techniques, innovative design strategies, and a better comprehension of patient variability are essential to optimize the safety, efficacy,and applicability of these systems in clinical practice.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-01-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/81</dc:identifier>
	<dc:identifier>10.62896/w1rxyz81</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 2, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/81/34</dc:relation>
	<dc:relation>10.62896/4jshxb39</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/82</identifier>
				<datestamp>2026-01-24T06:04:08Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Exploring the Versality of Chewable Tablets: A  Comprehensive Analysis</dc:title>
	<dc:creator xml:lang="en">Nikita Patil</dc:creator>
	<dc:creator xml:lang="en">Akash Yadav</dc:creator>
	<dc:creator xml:lang="en">Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">Tablet, Chewable tablet, Dosage form, Formulation techniques,  Evaluations</dc:subject>
	<dc:description xml:lang="en">Chewable dosage forms, such as tablets, soft pills, gums, and chewable squares, are essential components in a pharmacist&#039;s toolkit. They are designed to be broken and bitten between the teeth before administration, offering a solution for children struggling with swallowing and adults who find swallowing unpleasant. Chewable tablets are formulated to smoothly disintegrate in the mouth, either through chewing or without, characterized by a pleasant taste and a smooth texture upon disintegration, without any bitter or unpleasant aftertaste. These dosage forms are particularly valuable for geriatric and pediatric patients, as well as for individuals on the move who may not have immediate access to water. The formulation of chewable tablets involves critical factors such as flow, lubrication, disintegration, organoleptic properties, compressibility, compatibility, and stability. While these factors are shared with regularly swallowed tablets, the focus on the sensory aspects of the active drug substances, known as organoleptic properties, becomes a primary concern in chewable formulations. Formulators employ various approaches to achieve an optimal combination of formula and process, prioritizing the development of a product with favorable organoleptic properties. This emphasis on taste and texture makes chewable tablets a valuable option for enhancing medication adherence, particularly in populations facing challenges related to swallowing. In summary, chewable dosage forms play a vital role in addressing the diverse needs of patients, offering a user-friendly alternative for various age groups and situations. This comprehensive review paper explores the diverse landscape of chewable tablets, presenting a thorough examination of their advantages, disadvantages, ideal characteristics, formulation constituents, preparation techniques, and key evaluating various methods employed in the development of chewable tablets. Furthermore, it investigates the key pre-compression parameters such as Moisture content, angle of repose, Carr’s index etc, along with post-compression parameters including hardness, friability, thickness, disintegration, and dissolution etc.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-02-02</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/82</dc:identifier>
	<dc:identifier>10.62896/mg0v6x34</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 2, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/82/35</dc:relation>
	<dc:relation>10.62896/24akd520</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 International Journal of Pharmaceutical Drug Design</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/83</identifier>
				<datestamp>2026-01-24T06:04:57Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Ayurvedic Dosage Forms: An Updated Overview</dc:title>
	<dc:creator xml:lang="en">Pankaj Khuspe</dc:creator>
	<dc:creator xml:lang="en">Dipali Mane</dc:creator>
	<dc:creator xml:lang="en">Abhaysinh Hole</dc:creator>
	<dc:creator xml:lang="en">Amol Raskar</dc:creator>
	<dc:creator xml:lang="en">Ritesh Vyavahare</dc:creator>
	<dc:creator xml:lang="en">Amol Ban</dc:creator>
	<dc:creator xml:lang="en">Pranjali Kharmate</dc:creator>
	<dc:subject xml:lang="en">Ayurveda, Dosage forms, Traditional medicine, Churna, Kwatha, Vati,  Taila, Herbal formulations</dc:subject>
	<dc:description xml:lang="en">With its origins in antiquated Indian customs, ayurvedic medicine is still very important to healthcare. The foundation of this comprehensive approach is the wide range of Ayurvedic dosage forms. An updated overview of Ayurvedic dosage forms is given in this thorough examination, which also examines their modern applications, historical development, quality standards, and breakthroughs in science. In addition, the paper explores the difficulties associated with regulation and standards, providing future options for research and development. This updated review promotes a deeper understanding of the complex world of Ayurvedic dosage forms in the context of contemporary healthcare, serving as a vital resource for practitioners, academics, and policymakers alike as Ayurvedic techniques acquire recognition on a global scale.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-01-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/83</dc:identifier>
	<dc:identifier>10.62896/mte9wc10</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 2, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/83/36</dc:relation>
	<dc:relation>10.62896/5ctzdy97</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/84</identifier>
				<datestamp>2026-01-24T06:04:45Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Exploring Pregnancy Complications and  Interventions: A Comprehensive and In-Depth  Analysis for Enhanced Understanding and Medical  Approaches</dc:title>
	<dc:creator xml:lang="en">Km. Shiva</dc:creator>
	<dc:creator xml:lang="en">Km. Bhumika</dc:creator>
	<dc:creator xml:lang="en">Jiyaul Hak</dc:creator>
	<dc:creator xml:lang="en">Mukesh Kumar</dc:creator>
	<dc:creator xml:lang="en">Suraj Mandal</dc:creator>
	<dc:subject xml:lang="en">pregnancy, woman&#039;s life, treatment strategies, medication, high-risk  pregnancies</dc:subject>
	<dc:description xml:lang="en">Physical, hormonal, and emotional changes accompany pregnancy, which is a transforming and important time in a woman&#039;s life. While the majority of pregnancies go off without a hitch, a sizable percentage experience difficulties that endanger both the expectant woman and the growing fetus. The vast range of pregnancy difficulties are covered in this thorough review, from common problems like gestational diabetes and preeclampsia to uncommon ailments like placental abruption and ectopic pregnancies, the variety of treatments and management techniques accessible to medical practitioners to ensure both mother and child&#039;s wellbeing throughout difficult pregnancies. It looks at prenatal care, diagnostic techniques, and treatment approaches including bed rest, medication, and surgery. The necessity of collaborative decision-making with expectant women and the relevance of diverse healthcare teams in developing individualized treatment strategies are both highlighted. Moreover, the value of ongoing study and technology development in enhancing outcomes for high-risk pregnancies. It draws attention to the potential benefits of cutting-edge innovations in early identification, monitoring, and management of pregnancy problems, including telemedicine and artificial intelligence.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-01-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/84</dc:identifier>
	<dc:identifier>10.62896/8v7mzw43</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 2, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/84/37</dc:relation>
	<dc:relation>10.62896/6ybn5c53</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/85</identifier>
				<datestamp>2026-01-24T06:06:56Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A review on Phytochemistry and Pharmacology of medicinal  plant Bunium persicum (Boiss.) B.Fedtsch</dc:title>
	<dc:creator xml:lang="en">Shivali Sagar</dc:creator>
	<dc:creator xml:lang="en">Dr. Himanshu Joshi</dc:creator>
	<dc:subject xml:lang="en">Bunium persicum (Boiss.), Apiaceae, Phytochemistry, Pharmacological  activities</dc:subject>
	<dc:description xml:lang="en">Bunium persicum (Boiss.) B. Fedtsch is a valued medicinal plant belonging to the Apiaceae family that thrives throughout Asia, including Central Asia, Iran, Pakistan, Afghanistan, and India. Many pharmacological studies have shown the ability of this plant to exhibit antibacterial, and antioxidant characteristics, indicating a high potential for use in medicine and food. In traditional medicine, it is used to treat conditions such as digestive and urinary issues, diabetes, obesity, antispasmodic, anti-asthma, antiepileptic, diuretic, anticonvulsant and breast milk production. Furthermore, in the past two decades, several studies in phytochemistry and pharmacology have explored many bioactive compounds and their respective uses in essential oils, thus requiring more rigorous. This review is an extensive summary of the phytochemical and pharmacological activities as well as the traditional and therapeutic uses of this plant. Bunium persicum (Boiss.) B. Fedtsch has wide traditional and pharmacological uses in various pathophysiological conditions. We will review the various properties of Bunium persicum (Boiss.) B. Fedtsch (Kala Zeera) and focus on its various medicinal properties. We think that it is an attractive subject for further experiment.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-02-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/85</dc:identifier>
	<dc:identifier>10.62896/vhrxh740</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 3, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/85/38</dc:relation>
	<dc:relation>10.62896/bvb46503</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/86</identifier>
				<datestamp>2026-03-10T06:14:11Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Role of the Natural Super Disintegrant’s in Mouth Dissolving  Tablets</dc:title>
	<dc:creator xml:lang="en">Nandhini M</dc:creator>
	<dc:creator xml:lang="en">Voleti Vijaya Kumar</dc:creator>
	<dc:creator xml:lang="en">Yamuna Ramesh</dc:creator>
	<dc:creator xml:lang="en">Anisha Bashir</dc:creator>
	<dc:creator xml:lang="en">Suganya T</dc:creator>
	<dc:creator xml:lang="en">Sindhu C</dc:creator>
	<dc:creator xml:lang="en">A  Keerthika</dc:creator>
	<dc:creator xml:lang="en">P. Shanmugapandiyan</dc:creator>
	<dc:subject xml:lang="en">Mouth Dissolving Tablets, Plantago ovata, Fenugrek seeds, Dehydrated  Banana Power</dc:subject>
	<dc:description xml:lang="en">Oral route is the safest, most convenient, and economical route for administration of different drugs. Oral disintegrating tablets becoming very popular in the current scenario, as they facilely disintegrated in mouth within few seconds of the time after its administration without the need of water. Conventional dosage form has a limitations like dysphagia (arduousness in swallowing), in pediatric and geriatric patients, which have been overcome by oral disintegrating tablets. To prepare the same super disintegrating agents plays vital role. Natural Super disintegrants gained an advantage over the synthetic super disintegrants since they are chemically inert, non-toxic, less expensive, easily available, biodegradable in nature. Natural polymers like locust bean gum, banana powder, mango peel pectin and Hibiscus rosasinenses mucilage ameliorate the properties of tablet and utilized as binder, diluent, and superdisintegrants increase the solubility, dissolution of poorly water-soluble drug, decrease the disintegration time. Natural super disintegrants are obtained from various sources of natural origin and they are cost efficacious, nontoxic, biodegradable, eco-friendly, devoid of any side effect and renewable. From the different extensive literature review, It is observed that from the studies that natural polymers are safer and more efficacious than the synthetic polymers. The current review article is aimed to study the FDA-approved natural polymers utilized in fast dissolving tablets.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-02-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/86</dc:identifier>
	<dc:identifier>10.62896/p85zja75</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 3, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/86/39</dc:relation>
	<dc:relation>10.62896/vr7phn88</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/87</identifier>
				<datestamp>2026-03-10T06:18:10Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Gunda (Lasoda): A Comprehensive Review on Botanical  Description, Medicinal Significance, and Modern  Applications</dc:title>
	<dc:creator xml:lang="en">Piyush Kumar Singha</dc:creator>
	<dc:creator xml:lang="en">, Mahima</dc:creator>
	<dc:creator xml:lang="en">Mohd Shami</dc:creator>
	<dc:subject xml:lang="en">Indian cherry, Cathartin, Febrifuge, Contraceptive, Shelu, Sleshamatak</dc:subject>
	<dc:description xml:lang="en">Lasoda, also known as Sleshamatak (Cordia dichotoma), is a plant that is at the crossroads of contemporary science and Ayurvedic tradition. Cordia dichotoma is a member of the biggest genus in the Boraginaceae family, Cordia, with over 300 species recognised worldwide. This plant, also known as Shleshmatak, Shelu, Clammy Cherry, Indian Cherry, and Sebesten, is rich in medicinal qualities and contains a wide range of chemical elements, such as flavonoids, β-sitosterol, pyrrolizidine alkaloids, cathartin, and allantoin. Lasoda is highly regarded in Ayurvedic writings as a snehopaga, a one-stop cure for a variety of gastrointestinal issues. Beyond its customary uses, Cordia dichotoma has played a significant role in traditional medicine by providing remedies for ailments including ulcerative colitis, diabetes, wound healing, hepatoprotection, antibacterial activity, antiinflammatory characteristics, and anthelmintic qualities. The botanical description,chemical makeup, and variety of uses of Cordia dichotoma are succinctly summarised in this review, which also positions the plant as a prospective contender in the traditional and pharmaceutical domains, indicating its broad range of medicinal applications.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-02-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/87</dc:identifier>
	<dc:identifier>10.62896/ijpdd.v1.i318-26</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 3, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/87/40</dc:relation>
	<dc:relation>10.62896/4vt1nn60</dc:relation>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/99</identifier>
				<datestamp>2026-01-24T06:08:17Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A Compressive Review paper of aloe Vera and Papaya gel for  skin and hair Health</dc:title>
	<dc:creator xml:lang="en">Aarushi Ahlawat</dc:creator>
	<dc:creator xml:lang="en">Shipra Sharma</dc:creator>
	<dc:creator xml:lang="en">Yash Chauhan</dc:creator>
	<dc:creator xml:lang="en">Km. Shiva</dc:creator>
	<dc:subject xml:lang="en">aloe vera, papaya, skin</dc:subject>
	<dc:description xml:lang="en">Two herbs that have been traditionally used as medicines are papaya and aloe vera. A long time in various herbal remedies, including Ayurveda, Siddha, and homeopathy use cosmetics as medicine. Additionally, medications contain the inner tissue of an aloe Vera leaf is mucilaginous. The trade name Aloe Vera gel. Aloe Vera gel is devoid of which are responsible for anthraquinone Aloe has strong laxative effects. Aloe Vera is a formerly used to heal skin wounds (burns, cuts, gastrointestinal problems, eczema, and bug bites the anti-microbial, anti-inflammatory, and healing abilities for wounds. proteins and minerals. You can utilize the papaya fruit to shield your skin from Blackheads, pimples, acne, and other skin flaws. Thanks to the enzymes papain and chymopapain in skin care products Papaya may exfoliate skin softly and calm irritated skin. Papaya is one of the fruit crops that is produced both commercially and as a backyard vegetable due to its great flavor and high nutritional value. It is the most productive fruit crop with a productivity of 42.85 MT/ha. 6.01 million tons of fruit from 0.142 million hectares are produced there, accounting for around 6% of all fruit produced in India. Papaya output has expanded significantly from 0.805 million tons in 1991 to over 6.01 million tons currently, thanks to technological advancements and improved value chain management. Aloe vera and papaya gel are great for skin and hair. All hair problems, including curly hair and hair loss, will be resolved by doing this. The dark color of hair is enhanced and brightened with aloe vera. This hair gel not only detangles hair but also encourages hair growth. Two great hair treatments are aloe vera and papaya gel. All hair problems, especially those brought on by curly hair, will be resolved by doing this. Aloe vera brightens hair while adding to its dark color. This hair gel encourages hair growth in addition to detangling hair. Shower gels containing papaya and aloe vera are good natural skin care components.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-04</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/99</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 4, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/99/42</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/101</identifier>
				<datestamp>2026-01-24T06:08:26Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Phytoconstituents, Pharmacological Activities and  traditional uses of Costus Igneus, (Insulin Plant): Exploring  its Medicinal Potential</dc:title>
	<dc:creator xml:lang="en">Ranveer Singh</dc:creator>
	<dc:creator xml:lang="en">Kritika Aggarwal</dc:creator>
	<dc:creator xml:lang="en">Km. Shiva</dc:creator>
	<dc:creator xml:lang="en">Rohini Saini</dc:creator>
	<dc:creator xml:lang="en">Renu Chaudhary</dc:creator>
	<dc:creator xml:lang="en">Ritu  Verma</dc:creator>
	<dc:subject xml:lang="en">Costus igneus, Insulin plant, Leaf, Phytoconstituents, and Ayurvedic use,  Pharmacological activities, Marketed products.</dc:subject>
	<dc:description xml:lang="en">The Costus igneus, also called the insulin plant and found in Southeast Asia, has been used medicinally for a very long time. The plant was very recently brought to India, where it is grown as an attractive plant in south India. The insulin plant has a variety of phytochemical elements, including as steroid, alkaloid, flavonoid, triterpene, glycoside, and saponins. In the US, its leaves are consumed as a dietary supplement. diabetes type 2 therapy. The plant&#039;s tagline is &quot;A leaf a day keeps diabetes away&quot;. different pharmaceutical the effects on learning and memory, antioxidant activity, neuroprotective function, hypolipidemic function, anti-diabetic effect, anti-proliferative potential, anti-microbial, anti-urolithiatic property, anti-inflammatory potential, etc. are just a few of the activities. In order to develop a workable formula for human health in the future, the current review paper aims to investigate the many medicinal properties of the Costus igneus (insulin plant).</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-04</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/101</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 4, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/101/43</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/103</identifier>
				<datestamp>2026-01-24T06:08:07Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">EFFECTIVE TARGETED DRUG DELIVERY SYSTEM AN REVIEW OF  TRANSFEROSOME</dc:title>
	<dc:creator xml:lang="en">Pradyumn Tiwari</dc:creator>
	<dc:creator xml:lang="en">M. Alagusundaram</dc:creator>
	<dc:creator xml:lang="en">Namrata Mishra</dc:creator>
	<dc:creator xml:lang="en">Vijeta Bhattacharya</dc:creator>
	<dc:subject xml:lang="en">Transdermal, Extended, Bioactive, Transferosomes, Hydrophilic,  Hydrophobic</dc:subject>
	<dc:description xml:lang="en">Transdermal drug delivery is considered the safest and most effective method due to its constant and prolonged half-life and prevention of first-pass metabolism, and fewer side effects. Transfersomes, a type of malleable vesicle, are widely used for effective transdermal administration of bioactive materials. Researchers have added an edge activator to the lipid bilayer structure to alter their flexibility. Transferosomes can penetrate stratum-corneum lipid lamellar areas due to osmotic force or skin moisture. They can compress or collapse to fit through a tiny aperture and lose five to ten times their initial diameter before starting again. Research is ongoing on using transferosomes for targeted cancer treatment, as they can maintain an assembly of hydrophilic and hydrophobic components.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-03-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/103</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.4.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 4, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/103/44</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/108</identifier>
				<datestamp>2026-01-24T06:14:46Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">IODINE REPLENISHMENT THERAPY FOR WOMEN: A REVIEW ON TRANSDERMAL IODINE PATCHES</dc:title>
	<dc:creator xml:lang="en">Akanksha Tiwari</dc:creator>
	<dc:creator xml:lang="en">M. Alagusundaram,</dc:creator>
	<dc:creator xml:lang="en">Vijeta Bhattacharya</dc:creator>
	<dc:subject xml:lang="en">Iodine, skin, Patches, Iodine Deficiency Disorders, Transdermal Drug Delivery System, Bindi, Preformulated.</dc:subject>
	<dc:description xml:lang="en">Iodine deficiency is today’s time the leading cause of brain damage not just in India but around the globe, IDD are along with a host of other health complications. Most Iodine Deficiency Disorders are often both invisible and irreversible but at the same time, these are largely preventable. Indian, population is at a greater risk as the soil covering the Indian landmass lacks iodine, therefore the crops grown are also devoid of this element. Iodine-fortified salt mitigates the risk however this cannot compensate for the daily requirement of iodine in women, especially in the vulnerable rural areas of India. Transdermal drug delivery can be simply described as the method of transporting drug molecules across the skin via preformulated patches. These patches stick to the surface of the skin which absorbs the drug molecule and passes it to the bloodstream for further transport. The research aims to develop an alternative means for women in rural India to be equipped with the daily dose required of Iodine by applying a self-adhesive transdermal patch in the form of bindis with an iodine solution. Bindis are traditionally applied on the forehead by women in India. The bindis will work efficiently as a transdermal patch.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/108</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/108/47</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/109</identifier>
				<datestamp>2026-01-24T06:11:42Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Mentha Piperita Essential Oil in Nano-Hydrogel: An Effective Antifungal Strategy</dc:title>
	<dc:creator xml:lang="en">Rakhi Rani</dc:creator>
	<dc:creator xml:lang="en">Shamim Khan</dc:creator>
	<dc:creator xml:lang="en">Rustam Ekbbal</dc:creator>
	<dc:subject xml:lang="en">Mentha piperita essential oil, MPEO, Nano-Hydrogel, antifungal properties</dc:subject>
	<dc:description xml:lang="en">The utilization of essential oils, particularly Mentha piperita (peppermint) oil, in combating fungal infections has gained considerable attention due to their natural origin and potential efficacy. This abstract delves into the formulation of Mentha piperita essential oil within a nano-hydrogel matrix as a novel and effective antifungal strategy. The unique properties of nano-hydrogels, such as high-water content, biocompatibility, and controlled release capabilities, make them an ideal carrier for essential oils with therapeutic potential. The nano-hydrogel formulation of Mentha piperita essential oil offers several advantages over traditional antifungal agents. Firstly, the nano-scale structure of the hydrogel enhances the penetration of the essential oil into fungal cells, improving its antifungal activity. Secondly, the sustained release profile of the nano-hydrogel ensures prolonged exposure to the antifungal agent, leading to enhanced efficacy and reduced frequency of application. The antifungal activity of Mentha piperita essential oil is attributed to its rich composition of bioactive compounds, including menthol and menthone, which exhibit potent antimicrobial properties. When encapsulated within the nano-hydrogel, these bioactive compounds are protected from degradation and can exert their antifungal effects more effectively. Furthermore, the nano-hydrogel matrix provides a stable and convenient delivery system for Mentha piperita essential oil, facilitating its application in various antifungal formulations such as creams, gels, and ointments. This innovative approach holds promise for the development of next-generation antifungal therapies with improved efficacy, safety, and patient compliance. In conclusion, the integration of Mentha piperita essential oil into a nano-hydrogel represents a promising strategy for combating fungal infections, offering enhanced antifungal activity, prolonged release, and improved delivery characteristics. Further research and clinical studies are warranted to fully explore the potential of this novel antifungal approach in clinical practice</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/109</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/109/48</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/110</identifier>
				<datestamp>2026-01-24T06:11:52Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Role of Atomization in Pharmaceutical Industries</dc:title>
	<dc:creator xml:lang="en">Nikita Bhojney</dc:creator>
	<dc:creator xml:lang="en">Shiv Hardenia</dc:creator>
	<dc:creator xml:lang="en">Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">Automation, Qualification, Quality assurance (QA), Research and development (R&amp;D), Validation.</dc:subject>
	<dc:description xml:lang="en">Automating processes involves various control systems in industries with little to no human intervention to complete a variety of activities. The pharmaceutical industry has seen an increase in automation recently. Departments involved in manufacturing, packaging, labeling, and storage have all used automation. Manufacturing of specialized drugs is now possible thanks to automated equipment. Using the most recent technologies has had an impact on R&amp;amp;D as well. The SOP creation, auditing, qualifying, and equipment validation were the only conventional responsibilities of the QA department. The main focus of this study is relating to the use of automated technology in the pharmaceutical industry and how it affects the division in charge of pharmaceutical quality assurance. The Raman probe and other subjects are covered in this article. sDepartments involved in manufacturing, packaging, labeling, and storage have all used automation. The development of personalized pharmaceuticals has occurred as a result of the development of robotic devices. Therefore, these systems might be able to replace human inspectors. You can achieve greater accuracy and customization for a lower cost with this kind of technology.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/110</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/110/49</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/111</identifier>
				<datestamp>2026-01-24T06:12:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulation and evaluation of antidiarrheal sachet using Dalbergia sissoo leaves</dc:title>
	<dc:creator xml:lang="en">Ujjwal Verma</dc:creator>
	<dc:creator xml:lang="en">Amit Kr. Pandey</dc:creator>
	<dc:creator xml:lang="en">Saurabh Saraswat</dc:creator>
	<dc:creator xml:lang="en">Manvi Aggarwal</dc:creator>
	<dc:subject xml:lang="en">diarrhea, sachet, Dalbergia sissoo, phytotherapeutics</dc:subject>
	<dc:description xml:lang="en">Diarrhoea represents a global health concern, affecting millions of individuals every year. In the quest to discover effective remedies, the focus has shifted towards the exploration of natural alternatives. One such candidate is Dalbergia sissoo, commonly known as Indian Rosewood, a plant with a rich history of traditional medicinal use. This article delves into the exploration of Dalbergia sissoo and its potential as an anti-diarrhoeal agent.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/111</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/111/50</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/112</identifier>
				<datestamp>2026-01-24T06:12:13Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Hazards of Viruses and their Management</dc:title>
	<dc:creator xml:lang="en">Anurag Patel</dc:creator>
	<dc:creator xml:lang="en">Shiv Hardenia</dc:creator>
	<dc:creator xml:lang="en">Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">Virus, Zoonotic viruses, COVID 19, Epidemics and Pandemics, Vaccination</dc:subject>
	<dc:description xml:lang="en">This comprehensive review paper delves deeply into the intricate realm of viruses, investigating their classification, diversity, origins, and pathways of transmission. It sheds light on the significant threats that viruses pose to humanity, including human infectious diseases, outbreaks, pandemics, antibiotic resistance, and their link to cancer. Furthermore, it scrutinizes the challenges presented by the emergence and resurgence of viruses in the contemporary world. In response to these viral threats, the paper explores the range of strategies for managing them. Firstly, it delves into the essential role of vaccination and immunization programs in safeguarding populations against viral infections. Secondly, it critically examines the potential of antiviral therapies for treating viral diseases. Thirdly, it elucidates the importance of vector control methods as pivotal tools in controlling diseases transmitted by vectors. The “One Health” approach is investigated, emphasizing the interconnectedness of human, animal, and environmental health in the context of viral hazard management. Finally, the paper underscores the significance of quarantine and isolation measures in preventing the spread of infectious viruses. This comprehensive review paper furnishes an in-depth overview of the dangers posed by viruses and underscores the critical necessity of implementing effective management strategies to safeguard public health and global well-being.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/112</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/112/51</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/113</identifier>
				<datestamp>2026-01-24T06:12:23Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulation and Evaluation of Anti-Aging Cream Using Red Grapes Peel Extract</dc:title>
	<dc:creator xml:lang="en">Bharat Rana</dc:creator>
	<dc:creator xml:lang="en">Harsh Rana</dc:creator>
	<dc:creator xml:lang="en">Saurabh Saraswat</dc:creator>
	<dc:creator xml:lang="en">Pankaj Mahotra</dc:creator>
	<dc:subject xml:lang="en">: Reactive Oxygen Species (ROS), anti-ageing, radiation, oxidative stress, pigmentation, red grape peel.</dc:subject>
	<dc:description xml:lang="en">Aging is a natural process that affects everyone. As we age, our skin undergoes various changes, such as the loss of elasticity, the appearance of fine lines and wrinkles, and the development of age spots. Exposure to ultraviolet radiation from the sun is a significant extrinsic factor that generates reactive oxygen species (ROS), damaging dermal collagen and elastic fibers, leading to wrinkles, dryness, pigmentation, and loss of elasticity over time. While these changes are inevitable, there are ways to minimize their impact and maintain a youthful appearance. One such way is by using herbal anti-aging creams. In this article, we will explore the preparation of a herbal anti-aging cream using red grape peel extract which is rich in antioxidants and its potential benefits for the skin.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/113</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/113/52</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/114</identifier>
				<datestamp>2026-01-24T06:12:33Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Breast Cancer Post Market Monitoring of Drugs &amp; Procurement Strategies</dc:title>
	<dc:creator xml:lang="en">Rohit Kumar</dc:creator>
	<dc:creator xml:lang="en">Rupesh Gehlaut</dc:creator>
	<dc:creator xml:lang="en">Neelam Dhankar</dc:creator>
	<dc:subject xml:lang="en">Breast Cancer, Raloxifene, Tamoxifen, Bioavailability, Treatment, Toxic, Breast, Patient, Mechanism.</dc:subject>
	<dc:description xml:lang="en">Breast cancer represents a formidable global health challenge, necessitating continual advancements in treatment modalities and healthcare delivery. This research paper explores the pivotal intersection of post-market monitoring of breast cancer drugs and strategic procurement strategies, aiming to optimize patient outcomes while ensuring accessibility and affordability. Beginning with an overview of the current landscape, this paper investigates the methodologies and regulatory frameworks governing post-market monitoring breast cancer drugs. It scrutinizes the strengths and limitations of existing surveillance mechanisms, including spontaneous reporting systems and real-world evidence generation, and examines emerging trends such as Pharmacovigilance in digital health platforms. This paper delves into the complexities of drug procurement, analyzing various strategies employed by healthcare systems and stakeholders to enhance accessibility and affordability</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/114</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/114/53</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/115</identifier>
				<datestamp>2026-01-24T06:12:48Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulation of Nutraceutical Tablets Using Nutmeg and Cinnamon</dc:title>
	<dc:creator xml:lang="en">Lucky Kumar</dc:creator>
	<dc:creator xml:lang="en">Manasi Ranjit Karade</dc:creator>
	<dc:creator xml:lang="en">Neelam Dhankar</dc:creator>
	<dc:subject xml:lang="en">Nutraceuticals, Dietary supplements, Health benefits, Nutmeg, Cinnamon, Medicinal properties, Nutraceutical tablets</dc:subject>
	<dc:description xml:lang="en">Nutraceuticals are dietary supplements that provide health benefits beyond basic nutrition. They are derived from natural sources such as plants and are often used to prevent or treat various chronic diseases. Nutmeg (Myristica fragrans) and cinnamon (Cinnamomum zeylanicum/cassia) are two spices that have been traditionally used for their medicinal properties, and have gained attention as potential sources of nutraceuticals. Formulating nutraceutical tablets from nutmeg and cinnamon could provide a convenient and effective way to deliver their health benefits. However, manufacturing nutraceuticals into capsules and tablets is a tedious process that requires careful formulation and evaluation. This article will review the potential of nutmeg and cinnamon as nutraceutical ingredients, and discuss the formulation and evaluation of nutraceutical tablets containing these spices.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/115</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/115/54</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/116</identifier>
				<datestamp>2026-01-24T06:15:33Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulating a Natural, Effective Anti-Dandruff Shampoo with Rice Starch and Flaxseed</dc:title>
	<dc:creator xml:lang="en">Rahul Kumar</dc:creator>
	<dc:creator xml:lang="en">Soumik Chakraborty</dc:creator>
	<dc:creator xml:lang="en">Neelam Dhankhar</dc:creator>
	<dc:subject xml:lang="en">Rice starch, Flaxseed, Dandruff, Scalp, Flaking, Itching</dc:subject>
	<dc:description xml:lang="en">The constant evolution of scientific research has led to the development of innovative solutions for common problems. One such issue that has plagued the majority of the population is Dandruff. Dandruff is a common scalp disorder characterized by flaking, itching and irritation. While conventional anti-dandruff shampoos contain synthetic ingredients that can be harsh on the scalp, there is growing interest in developing natural, plant-based alternatives. Rice starch and flaxseed are two promising ingredients for formulating a mild, effective herbal antidandruff shampoo. This article will delve into the formulation and evaluation of an anti-hair fall shampoo that utilizes the nourishing properties of rice starch and flaxseed.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/116</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/116/55</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/117</identifier>
				<datestamp>2026-01-24T06:12:58Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Herbal Remedies for Arthritis: Advancements, Potential, and Future Prospects in Alternative Therapy</dc:title>
	<dc:creator xml:lang="en">Vivek Tripathi</dc:creator>
	<dc:creator xml:lang="en">Suraj Mandal</dc:creator>
	<dc:subject xml:lang="en">Herbs, Cytokines, Matrix metalloproteinase, Nitric oxide, Complementary and alternative medicine, Natural cure, Arthritis</dc:subject>
	<dc:description xml:lang="en">Arthritis is a leading global cause of disability and chronic health issues, with its pathophysiology characterized by the dysregulation of pro-inflammatory cytokines and enzymes, leading to elevated levels of prostaglandins, leukotrienes, and nitric oxide. Additionally, the expression of adhesion molecule matrix metalloproteinase and the excessive proliferation of synovial fibroblasts exacerbate the condition. The transcription factor nuclear factor κβ plays a crucial role in regulating these factors. Therefore, the development of drugs targeting these pathogenic mechanisms holds promise for arthritis treatment. However, current synthetic molecules often fall short due to their toxicity, side effects, or symptom recurrence upon cessation. In light of the urgent need for alternative treatments, traditional medicine offers a rich repository of herbal therapies. Recent scientific research has demonstrated the efficacy of these remedies in managing arthritis, leading to a surge in industrial interest and clinical trials for herbal medicines in treating various ailments, including arthritis. These meticulously designed clinical trials have significantly advanced our understanding of herbal treatments for arthritis.This review delves into the potential of herbal remedies as a promising alternative for arthritis therapy, highlighting current advancements and future prospects</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/117</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/117/56</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/118</identifier>
				<datestamp>2026-01-24T06:13:12Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Potential Implementation of Rabeprazole in Prevention of Acidity in GIT: Updated Mini-Review</dc:title>
	<dc:creator xml:lang="en">Triloki Prasad</dc:creator>
	<dc:creator xml:lang="en">Ritu Verma</dc:creator>
	<dc:creator xml:lang="en">Mohd. Shoaib</dc:creator>
	<dc:creator xml:lang="en">Shubham Aashiyan</dc:creator>
	<dc:creator xml:lang="en">Supriya Garg</dc:creator>
	<dc:creator xml:lang="en">Dipesh Kumar</dc:creator>
	<dc:creator xml:lang="en">Manoj Kumar</dc:creator>
	<dc:creator xml:lang="en">Akash Kumar</dc:creator>
	<dc:subject xml:lang="en">Proton pump inhibitor, Gastric acid, Rabeprazole GERD.</dc:subject>
	<dc:description xml:lang="en">Rabeprazole is a proton pump inhibitor. Pharmacodynamics data show rabeprazole can achieve optimal acid suppression since the first administration and can maintain this advantage in the following days of therapy. Moreover, rabeprazole has the highest pKa (~ 5.0, the pH at which a drug becomes 50% protonated), and hence the molecule can be activated at higher pH levels much faster than other PPIs. Due to its peculiar catabolic pathway, ie, a prevalent metabolism through a non-enzymatic pathway, rabeprazole is less susceptible to the influence of genetic polymorphisms for CYP2C19, resulting in minor influences on its pharmacokinetics and pharmacodynamics. To prevent symptomatic relapse, on-demand strategy with rabeprazole 10 mg daily appears to be ideal, due to its rapidity of onset; results on NERD patients have documented its superiority over placebo. Continuous treatment, however, up to 5 years, seems to achieve better results than on-demand therapy, particularly in patients with esophagitis</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/118</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/118/57</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/119</identifier>
				<datestamp>2026-01-24T06:13:24Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Transethosomes Novel Carrier: Promising Ultra deformable system for topical drug delivery</dc:title>
	<dc:creator xml:lang="en">Rani Yadav</dc:creator>
	<dc:creator xml:lang="en">M. Alagusundaram</dc:creator>
	<dc:creator xml:lang="en">Vijeta Bhattacharya</dc:creator>
	<dc:creator xml:lang="en">Pradyumn Tiwari</dc:creator>
	<dc:creator xml:lang="en">Namrata Mishra</dc:creator>
	<dc:subject xml:lang="en">Lipid nanoparticles, low bioavailability, transethosomes, medication delivery</dc:subject>
	<dc:description xml:lang="en">Lipid nanoparticles have been the subject of much investigation as frontline nanocarriers for medication and vaccine formulations due to the growing demand for novel drug delivery strategies. With benefits over conventional formulations such as reduced plasma fluctuations, first-pass metabolism, organ toxicity, and low bioavailability, transethosomes have come to light as a potentially effective treatment. This thorough analysis looks at manufacturing methods and assessment attributes for effective drug delivery, as well as the effects of formulation elements on the characteristics and efficient targeting of transethosomes. In order to demonstrate the adaptability and possibility for controlled release of transethosomes, the review also looks at their numerous routes of administration, such as transdermal, transvaginal, pulmonary, and ocular delivery. The review also looks at how photodynamic treatment and functionalization could improve the effectiveness of medication delivery</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/119</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/119/58</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/120</identifier>
				<datestamp>2026-01-24T06:13:34Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A Review on Emulgel: Promising Novel Carrier for Transdermal Drug Delivery System</dc:title>
	<dc:creator xml:lang="en">Divyanshi Kushwah</dc:creator>
	<dc:creator xml:lang="en">Vijeta Bhattacharya</dc:creator>
	<dc:creator xml:lang="en">Pradyumn Tiwari</dc:creator>
	<dc:creator xml:lang="en">Namrata Mishra</dc:creator>
	<dc:subject xml:lang="en">Emulgel, Hydrophobic, Dermatological, Bioavailability, Innovative Vesicular.</dc:subject>
	<dc:description xml:lang="en">Emulgels are a novel method of drug administration that takes advantage of the special qualities of gels to benefit hydrophobic medicinal moieties. In dermatological pharmacology, they are employed in conjunction with hydrophilic cornified cells to offer a barrier against hydrophilic and hydrophobic chemicals. Transparent gels are becoming more and more common in medicinal and cosmetic formulations. Because polymers can gel, they may be used as thickeners and emulsifiers to create stable emulsions and creams. Emulgels are perfect for topical medication administration since they have benefits in both traditional and innovative vesicular systems. They can also be expanded to include antifungal and analgesic medications. Topical drug delivery refers to the administration of medications via the skin, ocular, vaginal, and rectal channels, among others. Emulgels improve bioavailability and patient compliance because of their dual control and continuous release pattern, enhanced permeability, precise stability, and other characteristics. They are also thermodynamically strong.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/120</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/120/60</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/121</identifier>
				<datestamp>2026-01-24T06:13:43Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">NIOSOMES: CURRENT STATUS AND THEIR PROSPECTS</dc:title>
	<dc:creator xml:lang="en">Apurvi Pathak</dc:creator>
	<dc:creator xml:lang="en">Namrata Mishra</dc:creator>
	<dc:creator xml:lang="en">Vijeta Bhattacharya</dc:creator>
	<dc:subject xml:lang="en">Niosome, Cholesterol, Hydrophilic and Lipophilic drugs, Surfactant, Targeted delivery, Bioavailability Improvement, Factors, Applications</dc:subject>
	<dc:description xml:lang="en">A dermal patch that has medicinal properties is painless adhesive patch which puts on the skin surface to convey a particular dose of medicine passing through the skin and into the circulation. Non-Ionic surfactant-based vesicles, otherwise called niosomes, stand out enough to be noticed in drug fields because of their amazing conduct in typifying both hydrophilic and hydrophobic specialists. As of late, it has been found that these vesicles can work on the bioavailability of medications, and may work as another technique for conveying a few normal of remedial specialists, for example, chemical and protein drugs and gene materials with low poisonousness and wanted to focus on efficiency. Compared with liposomes, niosomes are significantly steadier during the plan interaction and storage. The required pharmacokinetic properties can be accomplished by streamlining part sort by surface modification. This original conveyance framework is likewise simple to get ready and scale up with low creation costs. In this paper, we sum up the formulation, method, and characterization of niosome and its applications in skin diseases like Acne dark spots.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/121</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/121/61</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/122</identifier>
				<datestamp>2026-01-24T06:13:52Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">PLUMERIA OBTUSA PHYTOCHEMISTRY AND PHARMACOLOGY: INSIGHTS INTO POTENTIAL THERAPEUTIC TARGETS</dc:title>
	<dc:creator xml:lang="en">Rohini Mishra</dc:creator>
	<dc:creator xml:lang="en">Preeti Anand</dc:creator>
	<dc:creator xml:lang="en">Rajat Saini</dc:creator>
	<dc:subject xml:lang="en">Plumeria obtuse, Phytochemistry, Pharmacology, Therapeutic targets, Bioactive compounds, Traditional medicine</dc:subject>
	<dc:description xml:lang="en">Plumeria obtusa, a plant belonging to the Apocynaceae family, has attracted a lot of interest lately because of its rich phytochemical profile and variety of pharmacological effects. This review sheds light on Plumeria obtusa&#039;s possible therapeutic targets by offering insights into the phytochemistry and pharmacology of the plant. Numerous bioactive substances have been found and classified after being separated from various plant sections. These include flavonoids, iridoids, and pentacyclic triterpenoids. Numerous pharmacological activities, such as antiinflammatory, antioxidant, antipyretic, antinociceptive, anticancer, and antiviral effects, are shown by these substances. Furthermore, Plumeria obtusa has been historically utilized in many cultures to cure a wide range of illnesses, such as cancer, fever, and skin conditions. The results of phytochemical and pharmacological investigations demonstrate Plumeria obtusa&#039;s medicinal potential and stress the need for further investigation to completely understand its modes of action and possible clinical uses.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/122</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/122/62</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/123</identifier>
				<datestamp>2026-01-24T06:14:05Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">PATENT PROVISION IN VARIOUS COUNTRIES</dc:title>
	<dc:creator xml:lang="en">Jaitvya Kalmodi</dc:creator>
	<dc:creator xml:lang="en">Shiv Hardenia</dc:creator>
	<dc:creator xml:lang="en">Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">Intellectual property rights, TRIP’s agreement, WIPO, patent types</dc:subject>
	<dc:description xml:lang="en">Intellectual property rights are the unique privileges given to people by their country to utilize the works of their imagination for a set amount of time. Patents, copyright, intellectual property rights include things like brand name, designs for industries, and geographical indications. A patent is the right that government has granted for entire disclosure of the innovations in exchange with a creation to the innovator. This review examines the laws and rights to intellectual property of several nations, including China, Japan, the United States, India and Europe. Examining both their influence upon the national interests and their effects on other countries. It is a comparison of all the laws surrounding patents in the aforementioned nations</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/123</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/123/63</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/124</identifier>
				<datestamp>2026-01-24T06:14:15Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A REVIEW ON USE OF NANOPARTICLES IN THE TREATMENT OF DIABETES MELLITUS</dc:title>
	<dc:creator xml:lang="en">Naina</dc:creator>
	<dc:creator xml:lang="en">Maninderjeet Kaur</dc:creator>
	<dc:creator xml:lang="en">Tichakunda Xavier Mharazanye</dc:creator>
	<dc:subject xml:lang="en">Diabetes mellitus, chronic metabolic disorder, hyperglycemia, diabetes mellitus management</dc:subject>
	<dc:description xml:lang="en">Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. This essay provides a comprehensive overview of diabetes mellitus, exploring its types, etiology, pathophysiology, diagnosis, and treatment and management strategies. Additionally, it discusses the emerging field of nanoparticle-based therapies and their potential use in diabetes mellitus management. A thorough understanding of these aspects is essential for effectively managing diabetes and improving patient outcomes.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/124</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 5, Vol. 1, 2024</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/124/64</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/126</identifier>
				<datestamp>2024-05-10T10:21:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Emulgel Innovations: Harnessing Cardiospermum Halicacabum for Arthritis Management</dc:title>
	<dc:creator xml:lang="en">Husain, Bushra</dc:creator>
	<dc:creator xml:lang="en">Vishvakarma, Prabhakar</dc:creator>
	<dc:creator xml:lang="en">Mandal, Suraj</dc:creator>
	<dc:subject xml:lang="en">Cardiospermum Halicacabum, Emulgel Innovations, Anti-Inflammatory Potency, Arthritis Management.</dc:subject>
	<dc:description xml:lang="en">This study investigates the creative use of Cardiospermum halicacabum in the advancement of Emulgel details for arthritis the board. With its traditional roots in Ayurvedic medication and arising logical proof supporting its anti-inflammatory properties, Cardiospermum halicacabum addresses a promising herbal contender for easing joint irritation and torment related with arthritis. By saddling the therapeutic capability of this plant, novel Emulgel definitions are intended to offer designated conveyance of dynamic mixtures, upgrading adequacy and patient consistence. Through a multidisciplinary approach integrating traditional information with present day drug development, this examination adds to the headway of elective therapies for arthritis the board, preparing for more secure and more compelling treatment choices.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/126</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 13-24</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/126/65</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/127</identifier>
				<datestamp>2024-05-10T10:21:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Exploring Carica Papaya Leaf-Based Preparations for Dengue Treatment: A Comprehensive Review</dc:title>
	<dc:creator xml:lang="en">Chakraborty, Abhas</dc:creator>
	<dc:creator xml:lang="en">Kumar, Mukesh</dc:creator>
	<dc:creator xml:lang="en">Ali, Sayad Ahad</dc:creator>
	<dc:subject xml:lang="en">Dengue, anti-inflammatory activities, carica papaya, Aedes mosquito</dc:subject>
	<dc:description xml:lang="en">The Dengue illness is a prominent worldwide health issue, especially in tropical and subtropical areas where the Aedes mosquito species reside. Despite substantial research efforts, there are currently no proven antiviral treatments available for dengue. In recent times, there has been a growing focus on the examination of alternative medicine, which encompasses the study of natural treatments produced from medicinal plants. The popularity of papaya, scientifically known as carica papaya, has risen because of its alleged therapeutic benefits, namely in the treatment of dengue fever. The purpose of this thorough review is to gather the current body of research on the possible effectiveness of formulations made from Carica papaya leaves in the treatment of dengue fever. The antiviral, immunomodulatory, and anti-inflammatory activities of Carica papaya leaf extracts are explained by thoroughly analysing in vitro research, animal models, and clinical trials to understand the pharmacological pathways involved. Additionally, we provide a summary of the different compositions and timing of administration used in scientific studies investigating the effectiveness of papaya leaf extracts in alleviating symptoms and decreasing the severity of dengue. In order to fully exploit the therapeutic benefits of Carica papaya in treating dengue fever, this study provides suggestions for future research and also evaluates the problems and constraints experienced during the present work. In order to eliminate dengue fever and improve worldwide public health results, it is crucial to create treatments that are easily accessible, reasonably priced, and secure. This study emphasises the need of combining traditional knowledge with scientific investigation.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/127</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 1-12</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/127/66</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/128</identifier>
				<datestamp>2024-05-10T10:21:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Benzothiazole Congenres and It’s Therapeutic Consequence: Mini statement</dc:title>
	<dc:creator xml:lang="en">Triloki Prasad</dc:creator>
	<dc:creator xml:lang="en">Surjeet Singh</dc:creator>
	<dc:creator xml:lang="en">Priya Bharti</dc:creator>
	<dc:creator xml:lang="en">Shrutikant Gupta</dc:creator>
	<dc:creator xml:lang="en">Madhu Sharma</dc:creator>
	<dc:creator xml:lang="en">Priyanka Yadav</dc:creator>
	<dc:creator xml:lang="en">Deepak Kumar</dc:creator>
	<dc:subject xml:lang="en">Benzothiazole, hetero compounds, scaffold, biological and pharmacological activities</dc:subject>
	<dc:description xml:lang="en">Benzothiazole are important class of hetero compounds because it has unique and versatile scaffold for experimental design. In recent year heterocyclic compounds and their derivatives have wide range biological and pharmacological properties, Benzothiazole analogues are used in evaluating new product that possesses different biological activities. Hence their structural modification produces new derivatives causes wide range of biological and pharmacological activities such as antimicrobial, antiviral, anti-inflammatory, anti-consultant etc. This review summarises the various effect of substituent to develop new derivatives having good pharmacological properties. Benzothiazole is an organic compound bearing a heterocyclic nucleus (thiazole) which imparts a wide spectrum of biological activities to it. The significant and potent activity of benzothiazole moiety influenced distinctively by nature and position of substitutions. This review summarizes the effect of various substituents in recent trends and approaches to design and develop novel benzothiazole derivatives for anticancer potential in different cell lines by interpreting the Structure- Activity Relationship (SAR) and mechanism of action of a wide range of derivatives.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-10</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/128</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.3</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 25-31</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/128/67</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/129</identifier>
				<datestamp>2024-05-14T10:27:59Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A REVIEW ARTICLE: MOUTH DISSOLVING TABLETS</dc:title>
	<dc:creator xml:lang="en">Vishakha Sahasrabuddhe</dc:creator>
	<dc:creator xml:lang="en">M. Alagusundaram</dc:creator>
	<dc:creator xml:lang="en">Vijeta Bhattacharya</dc:creator>
	<dc:subject xml:lang="en">Mouth dissolving tablet</dc:subject>
	<dc:subject xml:lang="en">Rapid disintegration</dc:subject>
	<dc:subject xml:lang="en">Superdisintegrant</dc:subject>
	<dc:subject xml:lang="en">Improved bioavailability</dc:subject>
	<dc:description xml:lang="en">Due to better accessibility and tolerability for patients, mouth dissolving tablet is the most essential and recommended way of drug delivery. One more difficulty can be solved by administering the new drug with the mouth dissolving tablet formulation so that the drug quickly dissolves and breaks in the mouth in fewer minute due to the effect of super disintegrating agents that maximize the pore structure of the formulation. Whenever, the medicines that interact with saliva exclude the need for water and discharge the medicine quickly. This article focused on standard selection of drug, features, technologies developed for the mouth dissolving tablets, and assessment methods. The major role played by the super disintegrant and inactive substances for enhancing the bioavailability of drug and improves the drug release in the oral cavities. </dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-14</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/129</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.4</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 32-39</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/129/68</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/130</identifier>
				<datestamp>2024-05-20T01:48:13Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulation and Assessment of Herbal Toothpaste utilizing extract from Pomegranates, Amla, Alum and Clove Oil</dc:title>
	<dc:creator xml:lang="en">Baibhaw Kumar</dc:creator>
	<dc:creator xml:lang="en">Nimish Batra</dc:creator>
	<dc:creator xml:lang="en">Deepti Chauhan</dc:creator>
	<dc:creator xml:lang="en">Pooja Mehra</dc:creator>
	<dc:subject xml:lang="en">Pomegranate extract, Amla extract, Alum, Clove oil, Dental plaque, Antimicrobial, Pain relief, Antibacterial, Antioxidant, oral pathogens</dc:subject>
	<dc:description xml:lang="en">The preparation and evaluation of a unique herbal toothpaste using extracts from clove oil (Eugenia caryophyllata), pomegranates (Punica granatum), amla (Phyllanthus emblica), and alum (potassium aluminumsulfate) are shown in this work. Pomegranate peel, amla fruit, alum, and clove oil were used in the formulation process to extract bioactive components, which were then included into a toothpaste base. The toothpaste was subjected to physicochemical characterisation in order to assess variables like stability, viscosity, and pH. Using standardized microbiological assays, the antibacterial activity of the herbal toothpaste was evaluated against common oral pathogens, such as Porphyromonasgingivalis and Streptococcus mutans. Additionally, in vitro and in vivo tests using animal models were used to examine the toothpaste&#039;s capacity to prevent plaque formation and lessen gingival irritation. The developed herbal toothpaste outperformed conventional toothpaste controls in terms of antibacterial effectiveness against tested microorganisms, according to the results. It also showed encouraging results in preventing the production of plaque and decreasing gingival irritation, suggesting that it could be a useful dental hygiene solution. Clove oil added to the herbal toothpaste formulation enhanced its analgesic and antibacterial qualities, balancing the effects of alum, amla, and pomegranate extracts. Eugenol, the main component of clove oil, has been demonstrated to have strong antibacterial action against dental pathogens and to relieve gingivitis and toothaches. The herbal toothpaste that has been created using extracts of pomegranates, amla, alum, and clove oil shows promise as a means of improving dental health. Utilizing these natural constituents&#039; synergistic benefits, the toothpaste provides a secure and efficient substitute for traditional oral hygiene solutions. In order to confirm its effectiveness, safety, and long-term advantages for maintaining oral health, more clinical research is necessary.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-20</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/130</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.5</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 40-44</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/130/69</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/131</identifier>
				<datestamp>2024-05-20T01:48:13Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Scope And Therapeutic Potential of Moringa Oleifera: Comprehensive Review</dc:title>
	<dc:creator xml:lang="en">Ravi Kumar</dc:creator>
	<dc:creator xml:lang="en">Mohd. Salman</dc:creator>
	<dc:creator xml:lang="en">Nasiruddin Ahmad Farooqui</dc:creator>
	<dc:creator xml:lang="en">Praveen Kumar</dc:creator>
	<dc:creator xml:lang="en">Dr. Samim Ahmad</dc:creator>
	<dc:subject xml:lang="en">Moringa oleifera, tree of life, miracle tree, phytopharmaceutical applications.</dc:subject>
	<dc:description xml:lang="en">Moringa oleifera, also known as the “tree of life” or “miracle tree,” is classified as an important herbal plant due to its immense medicinal and non-medicinal benefits. Traditionally, the plant is used to cure wounds, pain, ulcers, liver disease, heart disease, cancer, and inflammation. This review aims to compile an analysis of worldwide research, pharmacological activities, phytochemical, toxicological, and ethnomedicinal updates of Moringa oleifera and also provide insight into its commercial and phytopharmaceutical applications with a motive to help further research.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-20</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/131</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.6</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 45-50</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/131/70</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/132</identifier>
				<datestamp>2024-05-30T11:42:09Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/133</identifier>
				<datestamp>2024-05-20T03:17:21Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/134</identifier>
				<datestamp>2024-05-20T03:23:57Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Review on analytical quality by design method of improved stability of drug</dc:title>
	<dc:creator xml:lang="en">Lalita Tyagi</dc:creator>
	<dc:creator xml:lang="en">Priyanshu</dc:creator>
	<dc:creator xml:lang="en">Ranveer Singh</dc:creator>
	<dc:creator xml:lang="en">Ankur Gupta</dc:creator>
	<dc:creator xml:lang="en">Dr. Sanjeev Kumar</dc:creator>
	<dc:creator xml:lang="en">Mohd. Irshad</dc:creator>
	<dc:subject xml:lang="en">quality by design, analytical, QbD, A QbD</dc:subject>
	<dc:description xml:lang="en">The stability of pharmaceutical drugs is a critical factor affecting their efficacy, safety, and shelf-life. Traditional stability testing methods often lack efficiency and may not adequately predict real-world performance. Analytical Quality by Design (A QbD) has emerged as a systematic approach to ensure product quality by designing and controlling analytical procedures. This review explores the application of QbD methodologies in improving the stability of pharmaceutical drugs. The review begins with an overview of the principles of A QbD and its significance in pharmaceutical development. It then delves into the challenges associated with drug stability testing and the limitations of conventional approaches. Next, the application of A QbD principles in designing stability-indicating analytical methods is discussed, focusing on critical quality attributes (CQAs), risk assessment, and method development strategies. Finally, future directions and challenges in the application of A QbD for improving drug stability are discussed. Areas for further research and development, such as the integration of advanced analytical techniques and computational modelling, are identified to enhance the effectiveness of A QbD approaches in ensuring drug stability and quality.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-20</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/134</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.8</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 56-64</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/134/72</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/136</identifier>
				<datestamp>2024-05-26T05:59:31Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">AN OVERVIEW ON BARIATRIC SURGERY</dc:title>
	<dc:creator xml:lang="en">Sourabh Mahajan</dc:creator>
	<dc:creator xml:lang="en">Shiv Hardenia</dc:creator>
	<dc:creator xml:lang="en">Dinesh Kumar Jain</dc:creator>
	<dc:subject xml:lang="en">Bariatric Surgery, Obesity, Surgical Techniques, Long-term Outcomes</dc:subject>
	<dc:description xml:lang="en">This abstract provides a comprehensive overview of Bariatric Surgery, a transformative medical intervention for individuals struggling with obesity. The discussion encompasses the manifold benefits of Bariatric Surgery, elucidating its profound impact on weight loss, metabolic health, and overall well-being. The diverse array of Types of Bariatric Surgery is explored, offering insights into the various surgical approaches tailored to individual patient needs. The abstract delves into the intricacies of the Surgical Procedure and Techniques employed in Bariatric Surgery, shedding light on the advancements in minimally invasive techniques that enhance patient recovery and reduce postoperative complications. A critical analysis of Short-term and Long-term Outcomes follows, elucidating the immediate effects on weight loss, resolution of comorbidities, and sustained improvements in quality of life. Notably, the abstract emphasizes the importance of multidisciplinary collaboration in achieving holistic patient care and long-term success.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-26</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/136</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.9</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 65-76</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/136/73</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/137</identifier>
				<datestamp>2024-05-26T06:37:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Targeting Apoptotic Cell Death in Cancer Therapy: Chemotherapeutic Approaches</dc:title>
	<dc:creator xml:lang="en">Nagendra Singh</dc:creator>
	<dc:creator xml:lang="en">Preeti Anand</dc:creator>
	<dc:creator xml:lang="en">Km. Bhumika</dc:creator>
	<dc:subject xml:lang="en">Cancer therapy, apoptotic cell death, chemotherapeutic strategies, carcinogenesis</dc:subject>
	<dc:description xml:lang="en">One of the main goals of contemporary oncological research is to generate more potent and less harmful medicines by focusing on apoptotic cell death in cancer therapy. This review article offers a thorough summary of chemotherapeutic strategies targeted at causing cancer cells to undergo apoptosis. It starts off by going over what is now known about apoptosis, including how it affects carcinogenesis and how chemotherapy works on it. Extrinsic and intrinsic routes, among other processes involved in apoptotic cell death, are clarified, emphasizing important molecular participants including caspases, the Bcl-2 family, and death receptors. The ubiquitin/proteasome system and methods for controlling apoptotic proteins, including as p53 and NF-κB, are also discussed in the study. It also covers specific methods of inducing apoptosis, such focusing on caspases and the Bcl-2 family, in addition to using TNF, TRAIL, and p53-based treatments. The study also offers insights into the state of preclinical and clinical research in apoptotic cancer treatment, as well as the assessment of new chemotherapeutic drugs that target different apoptotic pathways. All things considered, this review article provides insightful information on the many approaches and possible targets for boosting apoptotic cell death in cancer therapy, opening the door for the creation of more powerful therapeutic approaches.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-26</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/137</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.10</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 77-87</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/137/74</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/138</identifier>
				<datestamp>2024-05-30T10:13:00Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulation And Evaluation of microemulsion based Allicin for the treatment of Staph Infection</dc:title>
	<dc:creator xml:lang="en">Rajat Rai</dc:creator>
	<dc:creator xml:lang="en">Dr. M K Gupta</dc:creator>
	<dc:creator xml:lang="en">Ankit Yadav</dc:creator>
	<dc:creator xml:lang="en">Omkar Singh</dc:creator>
	<dc:subject xml:lang="en">Microemulsions, Skin infections, Bacteria, Antibiotics, Co-surfactants</dc:subject>
	<dc:description xml:lang="en">Micro emulsions have several advantages over emulsions, such as low manufacturing costs, high solubility, good penetrating power, clarity and transparency, the ability to be sterilized through filtration, and thermodynamic stability over an extended length of time. One of the most important components in the creation of a micro emulsion was surfactants. Combining surfactants and co-surfactants can enhance the dispersion of oil in water. The skin acts as an amazing barrier against bacterial infections. Many bacteria touches or reside on the skin, yet most of the time they are unable to create an infection. In the event that bacterial skin infections do develop, they can impact any area of the body, no matter how big or tiny. Depending on how bad they are, they could be harmless or even deadly. Bacterial skin infections can arise when bacteria enter the skin through hair follicles or microscopic skin breaks brought on by burns, sunburns, animal or insect bites, wounds, or pre-existing skin diseases. People are prone to developing bacterial skin illnesses following a variety of activities, such as gardening in contaminated soil or swimming in a contaminated pond, lake, or ocean. Antibiotics used topically are drugs used to treat bacterial infections.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/138</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.11</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 88-94</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/138/75</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/139</identifier>
				<datestamp>2024-05-30T11:02:33Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Novel Hybrid Molecules for Anticancer Therapy: A Comprehensive Review</dc:title>
	<dc:creator xml:lang="en">Abhishek Mishra</dc:creator>
	<dc:creator xml:lang="en">Himanchal Sharma</dc:creator>
	<dc:creator xml:lang="en">Muskan Bhardwaj</dc:creator>
	<dc:subject xml:lang="en">Molecular, Hybridization, Anticancer, Agents, Cell Lines, In Vitro, Pharmacophore Novel, Hybrid, Molecules, Anticancer Therapy, Hybrid molecules, Anticancer therapy, Drug design, Combination therapy, Cancer treatment, and Cancer treatment.</dc:subject>
	<dc:description xml:lang="en">The investigation of novel hybrid molecules has been prompted by the search for effective anticancer medicines. These molecules offer intriguing pathways for battling cancer through creative processes, and they have been the subject of this investigation. This extensive study provides a synthesis of the existing literature on hybrid compounds that have been created for anticancer therapy. It sheds light on the various structural compositions of these molecules as well as the many mechanisms of action that they possess. The review begins with an overview of traditional anticancer techniques and the limits of those approaches. It then goes on to outline the logic for harnessing hybrid molecules, highlighting the potential of hybrid molecules to overcome resistance and boost therapeutic efficacy. The advantages of hybrid molecules over conventional medicines are highlighted, along with the many methodologies for building hybrid molecules, such as conjugation, combination, and hybridization of pharmacophores. In addition, molecular targets that are essential for the progression of cancer and treatment are investigated, which offers insights into the rational design of hybrid compounds. In this study, the significance of hybrid molecules in preclinical and clinical settings is highlighted by the presentation of sample case studies. These case studies provide light on the chemical structures, mechanisms of action, and therapeutic results of hybrid molecules. Techniques for synthesis and characterisation are investigated, with a particular focus on the significance of structure-activity relationship studies in the process of developing hybrid compounds for inhibitory efficacy against cancer. Additionally, the obstacles that are currently being faced in the field as well as the future approaches that are being pursued are discussed, which paves the way for further developments in the creation and translation of novel hybrid molecules for the treatment of cancer.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/139</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.12</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 95-108</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/139/76</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/140</identifier>
				<datestamp>2024-05-30T11:32:59Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Phytochemical Profiling and Isolation of bioactive compounds from Alstonia Scholaris flowers</dc:title>
	<dc:creator xml:lang="en">Naziya</dc:creator>
	<dc:creator xml:lang="en">Smriti Gohri</dc:creator>
	<dc:creator xml:lang="en">Sayad Ahad Ali</dc:creator>
	<dc:subject xml:lang="en">Alstonia Scholaris, Antibacterial, Antioxidant, Follicles, Latex, Phenolics</dc:subject>
	<dc:description xml:lang="en">Utilizing methanolic concentrates of Indian villain tree leaves, follicles, and plastic to assess their phytochemical arrangement, antibacterial action, and cancer prevention agent properties. The methanol removes were found to have antibacterial movement against both Gram +ve (Bacillus subtilis and Staphylococcus aureus) and Gram - ve (Escherichia coli, Pseudomonas aeruginosa) microorganisms by the utilization of well dissemination methods. To decide the cell reinforcement profiles of the methanol removes, we utilized ferric thiocyanate lessening tests, superoxide anion outspread searching, and 1,1-diphenyl-2-picryl-hydrazil (DPPH) free extremist rummaging. Pertinoids (97.3 mg QE/g DW), proanthocyanidins (99.3 mg CE/g DW), and phenolics (49.7 mg GAE/g DW) were all present in critical focuses in the leaf extricate as per its phytochemical examination. Follicle and plastic concentrates had comparative measures of proanthocyanidins, flavonoids, and phenolics. Yet, follicular concentrate had a lot higher proanthocyanidin contents (46.8 mg CE/gDW). The antibacterial exercises of plastic concentrate were the most grounded of the relative multitude of concentrates tried. While each of the concentrates displayed critical DPPH free extremist and superoxide anion rummaging capacities, just the leaf separate areas of strength for showed and ferrous particle chelating exercises. A. researcher&#039;s leaf, follicle, and plastic concentrates showed intense cell reinforcement attributes, as indicated by the review&#039;s outcomes. Conceivable antimicrobial impacts of plastic concentrate.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/140</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.6.13</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 109-114</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/140/77</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/142</identifier>
				<datestamp>2024-05-30T11:47:28Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Formulation and Evaluation of Herbal (Nelumbo Nucifera) Anti-Inflammatory Gel</dc:title>
	<dc:creator xml:lang="en">Priyanka Keshri, Shivam Kumar, Pradyumn Tiwari</dc:creator>
	<dc:subject xml:lang="en">Characterization, Dried Ethanolic Extract, Extensive Testing, Effective Spreadability.</dc:subject>
	<dc:description xml:lang="en">The gel has the safest, easily applicable and most effective due to its directly applicable to the infected part of the skin with minimal adverse effect. This research explores the development and characterization of an anti-inflammatory gel using lotus stem, a plant that has long been valued for its therapeutic qualities, especially its ability to reduce inflammation. Dried ethanolic extract of lotus stem was carefully blended with essential components like Carbopol 934, propylene glycol 400, methylparaben, propylparaben, and distilled water in precisely the right amounts to create the gel formulation. Triethanolamine was gradually added in order to maintain the ideal pH range (6.8–7) for skin compatibility. The developed product was subjected to extensive testing, which included analyses of its physical characteristics, pH, spreadability, viscosity, homogeneity, and potential for skin irritation in animal models. The results highlighted the gel&#039;s positive qualities, such as its visually pleasing look, even dispersion, and effective spreadability, indicating bright futures for its use in anti-inflammatory treatment.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-05-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/142</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 6, Vol. 1, 2024; 51-55</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/142/79</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/146</identifier>
				<datestamp>2024-06-19T15:22:41Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Development and Characterization of Mucoadhesive Microspheres Containing Rosiglitazone Maleate: A Comprehensive Review</dc:title>
	<dc:creator xml:lang="en">Porika Sunil*</dc:creator>
	<dc:creator xml:lang="en">Mohit Chaturvedi</dc:creator>
	<dc:subject xml:lang="en">Rosiglitazone Maleate, Mucoadhesive microspheres, Type 2 diabetes.</dc:subject>
	<dc:description xml:lang="en">This review provides a comprehensive analysis of the development and characterization of mucoadhesive microspheres encapsulating Rosiglitazone Maleate, a drug commonly used for managing type 2 diabetes. Mucoadhesive drug delivery systems have emerged as a promising approach for improving the bioavailability and therapeutic efficacy of orally administered drugs. This manuscript examines the methods of preparation, evaluation techniques, and potential advantages of using mucoadhesive microspheres for Rosiglitazone Maleate delivery.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-06-19</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/146</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.7.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 7, Vol. 1, 2024; 1-3</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/146/80</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/147</identifier>
				<datestamp>2024-06-20T00:28:38Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Comparative Study Between Generic and Ethical Drugs</dc:title>
	<dc:creator xml:lang="en">Shruti Singh Sengar, Dinesh Kumar Jain*</dc:creator>
	<dc:subject xml:lang="en">Generic drugs, Branded drugs, Bioequivalence, FDA approval, Hatch-Waxman Act.</dc:subject>
	<dc:description xml:lang="en">The pharmaceutical landscape is marked by the coexistence of two essential categories of drugs: generic and branded. This review article aims to comprehensively analyze the key aspects, including efficacy, safety, cost-effectiveness, and regulatory considerations, in the ongoing debate surrounding generic and branded drugs. This study systematically evaluates a vast body of literature and clinical trials, encompassing various therapeutic areas and disease conditions, to elucidate the similarities and differences between generic and branded pharmaceuticals. We explore the bioequivalence and quality control measures that underpin generic drug manufacturing, shedding light on their safety and effectiveness. Furthermore, this review delves into the cost-effectiveness of generic drugs, addressing their potential to reduce healthcare expenditure while maintaining therapeutic efficacy. We also discuss the impact of healthcare policies and regulations on the prescription and utilization of generic drugs across different regions. Through this comparative analysis, we aim to provide healthcare professionals, policymakers, and patients with a balanced perspective on the choice between generic and branded drugs. Our findings highlight the importance of individual patient needs, regulatory compliance, and healthcare infrastructure in shaping drug selection and utilization. Ultimately, this review underscores the significance of continued research and evidence-based decision-making in optimizing the use of generic and branded drugs, thereby enhancing healthcare outcomes and promoting accessible, affordable, and high-quality pharmaceutical care for patients worldwide.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-06-30</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/147</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.7.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 7, Vol. 1, 2024; 4-10</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/147/81</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/150</identifier>
				<datestamp>2026-03-10T07:01:37Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Floating Drug Delivery System: An Updated Review </dc:title>
	<dc:creator xml:lang="en">Narayan Arora</dc:creator>
	<dc:creator xml:lang="en">Nidhi Jain</dc:creator>
	<dc:creator xml:lang="en">Babita Kumar</dc:creator>
	<dc:subject xml:lang="en">floating drug delivery systems, FDDS, gastric emptying devices, gastric  residence times.</dc:subject>
	<dc:description xml:lang="en">The purpose of writing this review on floating drug delivery systems (FDDS) was to compile the recent literature with special focus on the principal mechanism of floatation to achieve gastric retention. The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail. Including floating drug delivery systems (FDDS), swelling and expanding systems, polymeric bio-adhesive systems, highdensity systems, modified-shape systems and other delayed gastric emptying devices. In this review, current &amp;amp; recently developments of Stomach Specific FDDS are discussed that helps to overcome physiological adversities like short gastric residence times and unpredictable gastric emptying times.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-06-19</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/150</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 7, Vol. 1, 2024; 11-14</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/150/82</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/151</identifier>
				<datestamp>2026-03-10T07:14:02Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Versatility of Schiff Base Pharmacophore By green approaches  and Its Therapeutics: Updated Mini Review</dc:title>
	<dc:creator xml:lang="en">Sivani</dc:creator>
	<dc:creator xml:lang="en">Nasir Ahmad Farooqui</dc:creator>
	<dc:creator xml:lang="en">Shamim Ahamad</dc:creator>
	<dc:subject xml:lang="en">Schiff base, microwaves irradiation, green chemistry approach, synthetic  route.</dc:subject>
	<dc:description xml:lang="en">Synthesis of bioactive heterocyclic Schiff base and its derivatives is the most noteworthy takes in heterocyclic chemistry. Classical and non-classical methods (microwave irradiation) were used to prepare Schiff bases from primary amines and several substituted benzaldehydes. These methodologies form an energy efficient and environmentally benign greener synthesis. This review highlights the crucial synthetic route for synthesising various bioactive Schiff base ligands and metal complexes.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-06-19</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/151</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 7, Vol. 1, 2024; 15-23</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/151/83</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/152</identifier>
				<datestamp>2024-08-08T06:03:47Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Development of a Stability-Indicating HPTLC Method for the  Quantitative Analysis of Mirabegron-A Comprehensive Review</dc:title>
	<dc:creator xml:lang="en">Desale Praneta Ravindra</dc:creator>
	<dc:creator xml:lang="en">Shukla Karunakar</dc:creator>
	<dc:creator xml:lang="en">Chaturvedi Mohit</dc:creator>
	<dc:creator xml:lang="en">Gupta Revathi</dc:creator>
	<dc:creator xml:lang="en">Jatav  Rakesh Kumar</dc:creator>
	<dc:creator xml:lang="en">Patel Rakesh</dc:creator>
	<dc:subject xml:lang="en">Stability, HPTLC, Mirabegron.</dc:subject>
	<dc:description xml:lang="en">Mirabegron, a β3-adrenoceptor agonist used for treating overactive bladder syndrome, requires robust analytical methods to ensure its stability and efficacy. High-performance thin-layer chromatography (HPTLC) has emerged as a valuable tool for the quantitative analysis of Mirabegron due to its simplicity, cost-effectiveness, and ability to separate complex mixtures. This review summarizes the development and application of stability indicating HPTLC methods for Mirabegron, focusing on methodology, validation parameters, and applications in pharmaceutical research and quality control. The method&#039;s ability to separate Mirabegron from its degradation products under various stress conditions makes it indispensable for ensuring drug potency and shelf-life. Future directions for enhancing HPTLC techniques in pharmaceutical analysis are also discussed.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-06-19</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/152</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 7, Vol. 1, 2024; 24-29</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/152/84</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/153</identifier>
				<datestamp>2024-08-08T06:19:03Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Ecofriendly Synthesis of Benzimidazole by Approaching Green  chemistry Principles</dc:title>
	<dc:creator xml:lang="en">Nasiruddin Ahmad Farooqui</dc:creator>
	<dc:creator xml:lang="en">Vishant Goel</dc:creator>
	<dc:creator xml:lang="en">Praveen Kumar</dc:creator>
	<dc:subject xml:lang="en">benzimidazole; green chemistry; pharmacological activity</dc:subject>
	<dc:description xml:lang="en">Benzimidazoles and their derivatives play an extraordinarily significant role as therapeutic agents, e.g., antiulcer, analgesic, and anthelmintic drugs. The organic synthesis of benzimidazoles and derivatives to obtain active pharmacological compounds represents an important research area in organic chemistry. The use of non-environmental organic compounds and application high energy synthetic methods, the production of waste, and the application of conventional toxic processes are a problem for the pharmaceutical industry and for these important drugs’ synthesis. The substituted benzimidazoles are summarized in this review to provide insight about their organic synthesis using ecofriendly methods, as well as their pharmacological activities.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-08-08</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/153</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 8, Vol. 1, 2024; 1-7</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/153/85</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/154</identifier>
				<datestamp>2024-08-08T06:25:36Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Synthesis and Antimicrobial Evaluation of 1,4 -Naphthoquinone  Derivatives as Potential Antibacterial Agents</dc:title>
	<dc:creator xml:lang="en">Ujjwal Sahu</dc:creator>
	<dc:creator xml:lang="en">Shamim Ahmad</dc:creator>
	<dc:creator xml:lang="en">Mohd. Mujahid</dc:creator>
	<dc:subject xml:lang="en">1,4‐Naphthoquinones, natural product, Pseudomonas aeruginosa,  Salmonella bongori.</dc:subject>
	<dc:description xml:lang="en">1,4‐Naphthoquinones are an important class of compounds present in a number of natural products. In this study, a new series of 1,4‐naphthoquinone derivatives were synthesized. All the synthesized compounds were tested for in vitro antimicrobial activity. In this present investigation, two Gram‐positive and five Gram‐negative bacterial strains and one pathogenic yeast strain were used to determine the antibacterial activity. Naphthoquinones tested for its antibacterial potencies, among seven of them displayed better antimicrobial activity against Staphylococcus aureus (S. aureus; 30–70 μg/mL). Some of the tested compounds showed moderate to low antimicrobial activity against Pseudomonas aeruginosa (P.aeruginosa) and Salmonella bongori (S. bongori; 70–150 μg/mL). In addition, most active compounds against S. aureus were evaluated for toxicity to human blood cells using a hemolysis assay. For better understanding, reactive oxygen species (ROS) generation, time‐kill kinetic study, and apoptosis, necrosis responses were investigated for three representative compounds.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-08-08</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/154</dc:identifier>
	<dc:identifier>10.62896/</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 8, Vol. 1, 2024; 8-13</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/154/86</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/155</identifier>
				<datestamp>2024-08-14T08:51:00Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Innovative Approaches in Vitiligo Treatment: The Role of Nano-Drug Delivery Systems in Enhancing Therapeutic Efficacy</dc:title>
	<dc:creator xml:lang="en">Nitish Nagdev*, Jiyaul Hak, Deeksha</dc:creator>
	<dc:subject xml:lang="en">Nanoemulsion, Microemulsion, Therapeutic Approach, Vitiligo</dc:subject>
	<dc:description xml:lang="en">Vitiligo is a condition characterized by the loss of pigmentation in the skin, which has a profound influence on the physical health, emotional state, and overall quality of life of those afflicted. The main objective of therapy is to regulate the immunological response by reducing oxidative stress. Nevertheless, the skin&#039;s cuticle acts as a barrier and the absence of specific drug accumulation leads to inadequate therapeutic results and adverse consequences. Nanotechnology has intriguing opportunities for the development of novel therapeutic approaches for vitiligo, while research in this field is currently constrained. This review provides a concise and thorough analysis of current research conducted on nano-drug delivery methods used in the treatment of vitiligo. Specifically, it focusses on liposomes, niosomes, Nano hydrogels, and nanoparticles. These investigations have achieved notable advancements by raising the effectiveness of drug loading and improving the ability of drugs to penetrate the skin. These results suggest three important concepts for topical nano-drug delivery systems in the treatment of vitiligo: boosting the penetration of drugs through the skin, improving the retention of drugs, and aiding the regeneration of melanin. The purpose of these approaches is to stimulate the development of topical medication delivery methods that can efficiently target and perhaps overcome vitiligo.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-08-14</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/155</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.9.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 9, Vol. 1, 2024; 1-13</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/155/87</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/156</identifier>
				<datestamp>2024-08-14T08:51:00Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Synthesis And Characterization of Indazole N-oxide Derivatives as antimicrobial activity</dc:title>
	<dc:creator xml:lang="en">Naeem*, Nasiruddin Ahmad Farooqui, Praveen Kumar</dc:creator>
	<dc:subject xml:lang="en">Indazole N-oxide derivatives, antimicrobial activity, Synthesis</dc:subject>
	<dc:description xml:lang="en">The synthesis and characterization of Indazole N-oxide derivatives were carried out with the aim of evaluating their antimicrobial potential. Indazole N-oxide is a heterocyclic compound known for its diverse biological activities, including antimicrobial properties. In this study, a series of Indazole N-oxide derivatives were synthesized through a multistep reaction process. The synthesized compounds were then characterized using various spectroscopic techniques, including Nuclear Magnetic Resonance (NMR) spectroscopy, Infrared (IR) spectroscopy, and Mass Spectrometry (MS). The antimicrobial activity of the synthesized derivatives was assessed against a panel of bacterial and fungal strains. The results demonstrated that several of the Indazole N-oxide derivatives exhibited significant antimicrobial activity, with certain compounds showing superior efficacy compared to standard antimicrobial agents. The structure-activity relationship (SAR) analysis indicated that the presence of specific functional groups on the Indazole N-oxide core significantly influenced the antimicrobial properties. These findings suggest that Indazole N-oxide derivatives have the potential to be developed as novel antimicrobial agents, offering an alternative approach to combat microbial resistance.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-08-14</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/156</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.9.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 9, Vol. 1, 2024; 14-21</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/156/88</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/157</identifier>
				<datestamp>2024-09-16T06:56:01Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Production and Chemical Constituents of Basil Oil (Ocimum Basilicum L) Extracted from Steam Distillation and Hydrodistillation Extraction Process</dc:title>
	<dc:creator xml:lang="en">Ela Srivastava*, Priyanka Mathur</dc:creator>
	<dc:subject xml:lang="en">(Ocimum basilicum L) Oil, Distillation, Yield, Chemical Composition</dc:subject>
	<dc:description xml:lang="en">Steam distillation and hydrodistillation are the two methods used to extract essential oil from (Ocimum basilicum L) Oil. This study demonstrated that both the steam distillation and hydrodistillation processes are appropriate for extracting the essential oil of (Ocimum basilicum L) Oil because of their ability to yield higher yields of 1.20±0.02% and 1.60±0.02%, respectively, and because of their faster extraction periods. After analysis with GC-MS (gas chromatography mass spectrometry) and GLC (gas liquid chromatography), the total number of major and minor chemical molecules were found to be approximately similar. That is, the total number of chemical molecules in the (Ocimum basilicum L) Oil obtained by using steam and hydro distillation extraction methods, respectively, were 29 and 32.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-16</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/157</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.10.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 10, Vol. 1, 2024; 1-5</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/157/89</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/159</identifier>
				<datestamp>2024-09-22T03:21:43Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Design, Synthesis and Antimicrobial Screening of Novel Benzothiazole Analogs</dc:title>
	<dc:creator xml:lang="en">R.N. Ingole*, S.A. Waghmare, K.U. Dongare, S.B. Sarkate</dc:creator>
	<dc:subject xml:lang="en">N-(2,6-substitutedimino-6H-1,3,5-dithiazin-4-yl)benzo[d]thiazol-2-amine, alky / aryl isothiocyanates, gram positive (+Ve) and gram negative (-Ve) bacteria.</dc:subject>
	<dc:description xml:lang="en">Recently, in a laboratory novel series of N-(2,6-substitutedimino-6H-1,3,5-dithiazin-4-yl)benzo[d]thiazol-2-amine (IIIaa-ee) was synthesized by refluxing 2-(5-substituted-2,4-dithiobiuret)benzo[d]thiazol-2-amine (Ia-e) with alky / aryl isothiocyanates (IIa-e) in acetone medium 1:1 proportion. The structures of all the synthesized compounds were justified on the basis of chemical characteristics, elemental analysis and spectral studies and their antimicrobial screening against the gram positive and gram-negative bacteria such as S. aureus, B. Subtilis, B. Megatherium, S. typhi, E. coli, and A. Aerogenes.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-22</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/159</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.10.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 10, Vol. 1, 2024; 8-13</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/159/90</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/161</identifier>
				<datestamp>2024-09-22T15:15:05Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Cost-Effectiveness and Budget Impact Analysis of New Drug Therapies: A Comprehensive Study in Pharmacoeconomics</dc:title>
	<dc:creator xml:lang="en">Anjali Singh</dc:creator>
	<dc:subject xml:lang="en">Cost-Effectiveness, Budget Impact, Analysis, Drug Therapies, Pharmacoeconomics</dc:subject>
	<dc:description xml:lang="en">This study highlights the economic viability of innovative medication therapies within healthcare systems by examining their cost-effectiveness and budget impact across neurological disorders, cancer, and cardiovascular diseases. With an incremental cost-effectiveness ratio (ICER) of $8,333 every Quality-Adjusted Life Year (QALY), Drug A has the best cost-effectiveness profile, according to the analysis, making it a desirable choice for healthcare providers. Drug B, on the other hand, has a higher ICER of $12,500 per QALY, but its substantial advantages to oncology offset its costs. In contrast, Drug C has a somewhat modest health gain and, at $15,000 per QALY, its ICER suggests that it be carefully evaluated. The budget impact analysis emphasizes the various cost ramifications of putting these cures into practice, highlighting how crucial strategic planning is to the adoption of new drugs. Additionally, sensitivity and scenario analyses show how differences in market entry tactics and medicine prices can have a big impact on budget impact and cost-effectiveness. The results support well-informed decision-making that strikes a compromise between improving patient outcomes and economic sustainability, offering legislators and healthcare professionals insightful information when implementing novel pharmacological treatments.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-22</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/161</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.10.3</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 10, Vol. 1, 2024; 14-23</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/161/92</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/163</identifier>
				<datestamp>2024-09-28T17:39:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Artificial Intelligence in Clinical Trials: Transforming Patient Recruitment, Data Management, and Drug Development Processes</dc:title>
	<dc:creator xml:lang="en">Krati Dhakad*, Pranjali Bawane, Amit Verma, Akanksha, Aiman Sifat, Swagatama Ghosh</dc:creator>
	<dc:subject xml:lang="en">Artificial Intelligence, Clinical Trials, Patient Recruitment, Data Management, Drug Development Processes.</dc:subject>
	<dc:description xml:lang="en">The clinical trials are important for the development of medical science since it becomes easier to test novel drugs, medical equipment, and even new methods in the treatment of a person. Only 10% of these studies were able to complete the entire process-from original drug design to post-marketing surveillance, which is slightly worrying. This low completion rate seriously jeopardizes the overall sustainability of clinical research and public health and healthcare economics. Increasing study designs and costs, along with other related difficulties in patient recruitment and data management, also work to worsen this problem. In this respect, AI has become a really powerful instrument that can revolutionize several aspects related to clinical trials. Thus, to gauge the effectiveness of AI in the sphere of patient recruitment efficiency, and the accuracy of data management along with meeting deadlines for the development of drugs, this paper would be carried out by a mixed-methods approach. The paper illustrates considerable achievements in the fields associated with AI technologies through qualitative views of experts along with the quantitative analysis of key indicators. According to the findings, AI has decreased input error in data by 25%, cut average development time for medication by 22%, and reduced total identification of patients by 30%. Besides, AI has also been enhanced to predict the efficacy of drugs with the precision of 13%. These outcomes therefore highlight how AI can accelerate the procedures of clinical trials and increase participant diversity, which may, in the long run, influence the outcome of the trail. This may thus open doors for health breakthroughs to be more efficient and timely delivered.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/163</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 1-10</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/163/93</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/167</identifier>
				<datestamp>2024-09-28T17:39:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A review of Nanoparticles in Drug Delivery: Recent advances and Future Prospects</dc:title>
	<dc:creator xml:lang="en">Vivek Kumar, Neha Yadav, Deepika Jaiswal, Meenu Kannaujiya, Kavita Gupta, Rahul Kumar</dc:creator>
	<dc:subject xml:lang="en">Nanocarriers, Nanomedicine, Nanoparticles drug delivery systems.</dc:subject>
	<dc:description xml:lang="en">Current research into the use of modified nanoparticles in drug delivery systems (DDSs) for therapeutic applications has yielded numerous fascinating nanocarriers. This study investigates the various traditional and modern conveyance techniques for pharmaceutical distribution. Because of the serious drawbacks of traditional DDSs, nanocarriers have garnered extensive attention. Nanocarriers, including polymeric nanoparticles, mesoporous nanoparticles, nanomaterials, carbon nanotubes, dendrimers, liposomes, metallic nanoparticles, nanomedicine, and tailored nanomaterials, are used as transport systems for targeted distribution to specific body regions. Nanomedicine has rapidly grown to treat a wide range of conditions, including brain cancer, lung cancer, breast cancer, cardiovascular illness, and many others. All of these nanocarriers have been studied both in vitro and in vivo. Nanomedicines have the potential to significantly improve human health in the coming years by incorporating more modern techniques into the medication delivery system.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/167</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 11-16</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/167/95</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/168</identifier>
				<datestamp>2024-09-28T17:39:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Radiotheranostics: Recent advancements and a strategy for future growth</dc:title>
	<dc:creator xml:lang="en">Vivek Kumar, Durgesh Pal, Pradeep Kumar, Sanjay Kumar, Vivekanand Tiwari, Rahul Kumar</dc:creator>
	<dc:subject xml:lang="en">Oncology, Radiothernostics, discovery, thyroid cancer, cancer stem cells.</dc:subject>
	<dc:description xml:lang="en">Radiotheranostics, injectable radiopharmaceuticals having anticancer activity, have advanced rapidly in the last decade. Although various formulations have been approved for human use, further radiopharmaceuticals are projected to be integrated into clinical practice within the next five years, potentially giving innovative therapy options for patients. Despite these advancements, other obstacles persist, such as logistics, supply chain, regulatory constraints, and education and training. This study intends to highlight recent advances in the area, inform practitioners about the value of radiotheranostics, and establish a framework for future development. Multidisciplinary methods to clinical trial design and therapy administration will be critical for the further development of this developing therapeutic modality.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/168</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.3</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 17-21</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/168/96</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/169</identifier>
				<datestamp>2024-09-28T17:39:51Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Nanotechnology in Targeted Drug Delivery for Cancer Treatment: A Comprehensive Review of Innovations and Future Applications in Medicine</dc:title>
	<dc:creator xml:lang="en">Deep Narayan Maurya*1, Arendra Pratap Singh2, Payal Saiju3, Reetesh Malvi4, Basu Venkateswara Reddy5, P. Jeyakani6</dc:creator>
	<dc:subject xml:lang="en">Nanotechnology, Nanocarriers, Targeted Drug Delivery, Chemotherapy, Cancer</dc:subject>
	<dc:description xml:lang="en">This study examines the developments in nanotechnology for targeted drug delivery in cancer therapy, emphasising breakthroughs that maximise therapeutic efficacy and minimise side effects. Conventional treatment approaches for cancer can have severe side effects and low specificity, making it a major worldwide health concern. Through the creation of diverse nanocarriers, such as liposomes, dendrimers, and polymeric nanoparticles, which may precisely target malignant cells while sparing healthy tissues, nanotechnology offers a transformative approach. The processes of both passive and active targeting are covered in the review, along with more recent developments such smart nanocarriers that react to tumour microenvironments. This review intends to provide insights into future possibilities for nanotechnology in medicine by synthesising current research and clinical applications, highlighting its potential to revolutionise cancer therapy and enhance patient outcomes.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-09-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/169</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.4</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 22-31</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/169/97</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header status="deleted">
				<identifier>oai:ojs2.literaryvoiceglobal.in:article/170</identifier>
				<datestamp>2024-10-21T09:32:56Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/171</identifier>
				<datestamp>2024-10-21T09:39:22Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Molecular Imagine of Glutamate Receptor: Updated Statement </dc:title>
	<dc:creator xml:lang="en">Mansi Giri*, Triloki Prasad, Abhinay Gupta, Arabind Kumar, Shivani Sharma, Dr. Priyanka, Preeti Pal, Priti Singh, Shubham Ashiyan</dc:creator>
	<dc:subject xml:lang="en">Glutamate receptors, positron emission tomography, excitatory synapse</dc:subject>
	<dc:description xml:lang="en">Sub-atomic imaging with positron outflow tomography (PET) and single photon emanation registered tomography (SPECT) is a deeply grounded and significant in vivo procedure to assess key natural cycles and unwind the job of synapse receptors in different neuropsychiatric problems, serotonin, and narcotic receptors, however relating improvement of radiotracers for receptors of glutamate, the super excitatory synapse in mammalian mind, has filled behind. This situation has persevered regardless of the focal significance of glutamate neurotransmission in mind physiology and in problems like stroke, epilepsy, schizophrenia, and neurodegenerative sicknesses. We currently audit the condition of improvement of radio ligands for glutamate receptor imaging, putting primary accentuation on the appropriateness of accessible ligands for solid in vivo applications. We give a short record of the radio manufactured approach for chosen particles. </dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-10-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/171</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.5</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 32-42</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/171/99</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/172</identifier>
				<datestamp>2024-10-21T09:41:52Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A Compressive Review of the Moringa Oleifera Plant: Phytochemistry and Pharmacological Significance</dc:title>
	<dc:creator xml:lang="en">Afreen Kadir*, Shourya Pratap</dc:creator>
	<dc:subject xml:lang="en">Phytochemical, Hypertension, Anti-diuretic, Ulcer, Pharmacological significance.</dc:subject>
	<dc:description xml:lang="en">The pantropical plant Moringa oleifera has now established itself in Afghanistan, both East &amp;amp;West Africa and Florida. Apart from its remarkable nutritional value in many regions of the world, Moringa oleifera is widely recognized for the significant medical advantages it provides. Many of the traditional folklore claims regarding the medicinal uses of Moringa oleifera morphological parts for a variety of ailments, including heart problems, fevers, inflammation, digestive disorders, asthma, intestinal problems, and rheumatism, have been supported by scientific studies conducted in the last few decades. Numerous pharmacological properties, including analgesic, anti-inflammatory, diuretic, antioxidant, anti-hypertensive and anti-tumor activities, are possessed by Moringa oleifera. Moreover, Moringa oleifera has a number of phytochemicals, some of which are highly valued for their potential medical applications. It is said that every portion of Moringa oleifera has health benefits, adding to the plant&#039;s variety and usefulness as a remedy. An updated summary of the scientific literature on the Phytochemistry and pharmacological importance of Moringa oleifera will be provided in this review.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-10-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/172</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.6</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 43-51</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/172/100</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/175</identifier>
				<datestamp>2024-10-22T10:06:16Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">A Cross-Sectional Study on Knowledge, Attitude and Practice Towards Reporting Adverse Drug Reactions among Healthcare Professionals at a Tertiary Care Associated Hospital of Government Medical College, Baramulla, Kashmir</dc:title>
	<dc:creator xml:lang="en">Arjumand Maqbool*, Shakil U Rehman</dc:creator>
	<dc:subject xml:lang="en">Adverse Drug Reaction, Practice, Healthcare professionals.</dc:subject>
	<dc:description xml:lang="en">Background: A study performed on Vigibase (WHO Pharmacovigilance data base) by collecting data from more than 30 countries, revealed that &amp;gt;23 million reports of ADRs were forwarded to the Uppsala Monitoring Centre by national pharmacovigilance systems. This study also reported 1.34% ADRs as fatal and more than 50% of reports included male patients. Several studies haves shown that the ADRs reported during hospital stay range from 1.7% to 32.7%. In developed countries, this range from 6.7% to 12.3% It was also reported that &amp;gt;75 years was the most commonly affected age group in the total population. Several studies haves shown that the ADRs reported during hospital stay range from 1.7% to 32.7%. In developed countries, this ranges from 6.7% to 12.3%. In India, the reported incidence of adverse drug reactions ranges from 3.7% to 32.7%. &amp;nbsp;Another study from Srinagar concluded the overall incidence of ADR was found to be 6.23% and the average direct cost for ADR treatment per patient was US$ 65. The most significant challenge in ADR management is under reporting. An estimated 94% of ADRs going unreported globally. To enhance the reporting rate, it is essential to improve the knowledge, attitude, and practice (KAP) of all healthcare professionals. Materials and Methods: The conducted study was a cross-sectional study, was carried out in the month of August among healthcare professionals by using a pre designed questionnaire developed on the basis of literature review and was divided into 4 parts (sociodemographic characteristics, knowledge, attitude and practice of the study participants). Data were collected and analyzed using descriptive statistics of frequency and percentage. Results: In our study we found that maximum number of the healthcare professionals had good knowledge about the definition of Pharmacovigilance (70%) and its purpose (58%). Most of them had good attitude towards reporting ADR as a professional obligation (90%). However, very less (22.67 %) have reported ADRs and only 10% (n=30) have reported more than 10 ADRs. It was also seen that the reason for not reporting the ADR was difficulty to decide whether ADR has occurred or not, given by maximum number (37 %), lack of time (26.67%) and assuming that one ADR makes no significant contribution. Conclusion: As evident from the findings, our study revealed that even though most of the healthcare professionals had an acceptable knowledge and attitude towards reporting Adverse Drug Reactions but there was lack of reporting Adverse Drug Reactions among the healthcare professionals. </dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-10-22</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/175</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.11.7</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 11, Vol. 1, 2024; 52-59</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/175/102</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/177</identifier>
				<datestamp>2024-11-06T13:10:27Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">The Role of AI in Modernizing Clinical Trials: From Patient Selection to Data Management</dc:title>
	<dc:creator xml:lang="en">Dr. Anusha Dewan, Dr. Sanjeev Kumar, Namrata Bhutani, Dr. Rohit Kumar Tomer</dc:creator>
	<dc:subject xml:lang="en">Clinical Trials, Artificial Intelligence, Patient Selection, Data Management, Machine Learning</dc:subject>
	<dc:description xml:lang="en">Aim: This study aimed at researching the transformative role that artificial intelligence has played in making clinical trials more efficient and effective-particularly concerning patient selection, trial design, and data management. Purpose: The main objective for this study will be to search, identify, and critically analyze various AI technologies in machine learning, natural language processing, predictive analytics, and their corresponding applications in clinical trials, focusing on using these novel approaches to bypass inefficiencies of the traditional approach and improve the outcomes of a clinical trial. Method: A descriptive research design was used, drawing on a standardized online survey conducted among 200 professionals involved in clinical trials. The survey collected the following: some relatively objective numerical data regarding the use of AI tools and problems encountered while managing data, as well as perceived outcomes from the inclusion of AI in clinical trials. Result: The key findings were that machine learning algorithms dominated with 40%, while the natural language processing aspect represented 30%. Among the challenges noted regarding data management was the integration of data, that reached 35% and quality of data is also at 30%. AI-driven outcomes improved patient selection and the efficiency of trial design. Conclusion: Integration of AI technologies in clinical trials would modernize research practices, meet the challenge of data management, and generally improve the efficiency of a trial. The findings reflect that investment into such tools needs to continue so results from trials can be successful and healthcare solutions are continuously improved.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-11-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/177</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.12.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 12, Vol. 1, 2024; 1-8</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/177/103</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/178</identifier>
				<datestamp>2024-11-07T16:57:30Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Novel Synthesis of 5-Subtituted 1,3-Oxazole-Based Molecules Via Van Leusen Oxazole Synthesis as Anti-Microbial Activity</dc:title>
	<dc:creator xml:lang="en">Aniket Pundir*, Dr. Nasiruddin Ahmad Farooqui, Dr. Shamim Ahmad, Jyoti Yadav</dc:creator>
	<dc:subject xml:lang="en">Anti-microbial, oxazole, microbial activity.</dc:subject>
	<dc:description xml:lang="en">Oxazole is heterocyclic five membered nucleus that explored improvement of novel mixtures with promising restorative exercises. In this manner, these mixtures have been blended as target structures by numerous analysts and were assessed for their natural exercises. Because of restricting with a far reaching range of receptors and chemicals effectively in natural frameworks through different communications, oxazole-based particles are turning into sort huge heterocyclic core, which stand out enough to be noticed from scientists worldwide, driving them to combine assorted oxazole subsidiaries.most suitable procedures to get ready oxazole-based restorative mixtures. In this survey, we sum up the new advances of the union of oxazole-containing particles using van Leusen oxazole combination expecting to search restorative mixtures, which are significant data revelation and amalgamation.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-11-07</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/178</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.12.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 12, Vol. 1, 2024; 09-20</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/178/104</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/179</identifier>
				<datestamp>2024-11-07T17:13:37Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Green Chemistry: Sustainable Approaches in Chemical Synthesis</dc:title>
	<dc:creator xml:lang="en">Rani Jitendrasigh Rajput, Vinayak Mahadeo Shejol</dc:creator>
	<dc:subject xml:lang="en">Green chemistry, atom economy, catalysis, sustainable solvents, energy efficiency, hazardous waste reduction, renewable feedstocks, microwave synthesis, supercritical CO₂, photochemistry.</dc:subject>
	<dc:description xml:lang="en">Green chemistry, introduced by Anastas and Warner, represents a sustainable approach to chemical synthesis aimed at minimizing environmental impacts, reducing waste, and enhancing resource efficiency. This review discusses key principles of green chemistry, such as atom economy, the use of green solvents like water and supercritical CO₂, and catalysis as pivotal strategies for reducing hazardous waste and energy consumption. Advancements in energy-efficient processes, like microwave-assisted synthesis and photochemistry, and the push for safer reagents like hydrogen peroxide further contribute to the goals of sustainability in chemical manufacturing. The integration of green chemistry into industrial processes is crucial for addressing global environmental challenges.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-11-07</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/179</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.12.3</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 12, Vol. 1, 2024; 21-31</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/179/105</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/180</identifier>
				<datestamp>2024-11-09T16:48:10Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Hydrogel Based Control Release Drug Delivery for Cancer Treatment: A Review</dc:title>
	<dc:creator xml:lang="en">Shraddha. P. Vaishnav, Tanuja. V. Deore, Komal. M. Deore, Sarthak. M. Aher, Ashay. S. Pachpute, Pranjali. P. Deshmukh, Sanved. B. Pagar, Vinod. A. Bairagi</dc:creator>
	<dc:subject xml:lang="en">Hydrogels, biocompatibility, high-water content, cancer treatment</dc:subject>
	<dc:description xml:lang="en">Hydrogels, due to their tunable physical properties, biocompatibility, and high-water content, have emerged as promising materials for controlled drug delivery in cancer therapy. This chapter explores the application of hydrogel-based drug delivery systems in cancer treatment, emphasizing the mechanisms of controlled drug release, various hydrogel formulations, and recent advancements in hydrogel technologies tailored for oncology. Special attention is given to the incorporation of nanoparticles and stimuli-responsive hydrogels for targeted and effective cancer treatment. By reviewing the current state of research, this chapter provides insights into the therapeutic potential, challenges, and future perspectives of hydrogel-based drug delivery systems in oncology.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-11-09</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/180</dc:identifier>
	<dc:identifier>10.62896/10.62896/ijpdd.1.12.4</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Number 12, Vol. 1, 2024; 32-42</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/180/106</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/181</identifier>
				<datestamp>2025-01-22T15:54:57Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Evaluation of the Anti-hypertensive Activity of Ethanolic Leaves Extract of Euterpe Oleracea Experimental Animal</dc:title>
	<dc:creator xml:lang="en">Md Shahbuddin, Praveen Kumar, Shamim Ahmad</dc:creator>
	<dc:subject xml:lang="en">Euterpe oleracea, Anti-hypertension, Histopathology and Serum Concentration of total Cholesterol</dc:subject>
	<dc:description xml:lang="en">Hypertension, or high blood pressure, is a prevalent and serious disorder that is linked to several health consequences, including premature death and cardiovascular disease. It is the primary aetiology for angina, myocardial infarction, stroke, heart failure, and renal failure. According to the World Health Organisation, hypertension is the third leading cause of death globally, responsible for nearly one in eight deaths. Cardiovascular problems provide a considerable contribution to illness and death, especially in the Eastern Mediterranean area, where 26% of individuals have hypertension. Annually, there are four million deaths and billions of people affected. The prevalence of hypertension is increasing as a result of variables such as a growing elderly population, higher rates of smoking, and changes in nutrition and lifestyle. Despite the availability of several antihypertensive drugs, they often lead to undesirable outcomes, including renal and gastrointestinal problems. Consequently, there is a growing fascination in herbal remedies, which are both more economical and have less negative consequences. This research examines the therapeutic benefits of using ethanolic leaf extract from Euterpe oleracea to treat hypertension. Over a span of five weeks, rats were given ethanol orally at a dosage of 5 g/kg/day, leading to an elevation in their blood pressure. Afterwards, the rats were divided into groups that were administered normal saline, ethanol, advanced marine (10 mL/kg), Nifedipine (10 mg/kg), or Euterpe oleracea extract (100 mg/kg and 200 mg/kg). The findings demonstrated that ethanol had a notable impact on arterial pressure and heart rate, whereas the administration of Euterpe oleracea and Nifedipine led to a substantial decrease in mean arterial pressure. Additionally, these treatments resulted in better cholesterol levels, liver and kidney function, as well as antioxidant status in hypertensive rats. The findings suggest that the extract of Euterpe oleracea has strong antihypertensive, hypolipidemic, and antioxidant effects, making it a potential therapy for hypertension</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-12-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/181</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.13.1</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Issue 13, Vol. 1, 2024; 1-9</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/181/107</dc:relation>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/181/115</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/183</identifier>
				<datestamp>2024-12-24T07:11:59Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Innovations in Drug Design: Revolutionizing Therapeutics Through Cutting-Edge Technologies</dc:title>
	<dc:creator xml:lang="en">Prabhat Singh, Geeta Rawat, Himanshi Gupta, Neha Kumari</dc:creator>
	<dc:subject xml:lang="en">Drug Discovery, Innovative Approaches, Targeted Therapeutics, Artificial Intelligence, Machine Learning, High-Throughput Screening, Rational Drug Design, Personalized Medicine, Precision Treatments, Drug Delivery Systems, Nanotechnology</dc:subject>
	<dc:description xml:lang="en">Drug discovery is a dynamic field constantly evolving with the aim of identifying novel therapeutic agents to combat various diseases. In this review, we present an overview of recent advances in drug discovery, highlighting innovative approaches and targeted therapeutics that have emerged in the last few years. The review covers a range of cutting-edge techniques and strategies used in drug design and development, including artificial intelligence and machine learning-based approaches, high-throughput screening, and rational drug design. Additionally, we discuss the significant progress made in the field of targeted therapeutics, with a focus on personalized medicine and precision treatments that offer improved efficacy and reduced side effects. Furthermore, we explore the latest breakthroughs in drug delivery systems and nanotechnology, which have paved the way for enhanced drug targeting and bioavailability. This comprehensive review aims to provide insights into the most promising developments in drug discovery, offering potential avenues for the future of medicine.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-12-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/183</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.13.2</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Issue 13, Vol. 1, 2024; 10-15</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/183/108</dc:relation>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/183/116</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/184</identifier>
				<datestamp>2024-12-24T07:11:59Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Biological Potential of Culinary Herb Oregano (Origanum Vulgare)</dc:title>
	<dc:creator xml:lang="en">Vandana Pokhriyal*, Kapil Kalra, Vinita Chauhan, Saumya Mishra, Urvashi Negi, Subodh Negi</dc:creator>
	<dc:subject xml:lang="en">Origanum vulgare L., Pharmacological, Traditional uses.</dc:subject>
	<dc:description xml:lang="en">In Lamiaceae family, Origanum vulgare L. (O. vulgare) is a significant medicinal herb. With an emphasis on the mechanisms of action of the most significant phytochemicals from O. vulgare subspecies, we described in the current study the critical evaluation of traditional applications, phytochemistry, and antimicrobial capabilities of O. vulgare and its subspecies. O. vulgare&#039;s volatile (essential oil) and non-volatile phenolic components (phenolic acids &amp;amp; flavonoids) are its most significant phytochemicals. Thymol and carvacrol, which are present in high concentrations in O. vulgare essential oil (EO), have outstanding antibacterial action either by themselves or in conjunction with other antibiotics.
Interesting findings have been published regarding the exceptional antimicrobial properties of O. vulgare infusions or tea products containing a high concentration of essential oil (EO) against bacterial and fungal microorganisms that are resistant to multiple drugs, including Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, and Escherichia coli. Enzyme inhibition, efflux pump inhibition, ATP depletion, suppression of biofilm formation, and cytoplasmic membrane damage are O. vulgare&#039;s primary antibacterial strategies. Several in-vitro and in-vivo investigations have verified the hirtum subspecies&#039; antibacterial properties. The clinical and preclinical studies demonstrating the antibacterial properties of O. vulgare and its subspecies are supported by the current review.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-12-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/184</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.13.3</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Issue 13, Vol. 1, 2024; 16-20</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/184/109</dc:relation>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/184/117</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<record>
			<header>
				<identifier>oai:ojs.ijpdd.org:article/185</identifier>
				<datestamp>2024-12-24T07:11:59Z</datestamp>
				<setSpec>files:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc
	xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
	xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/
	http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Smart Drug Delivery Solution: Review on Targeted Drug Delivery</dc:title>
	<dc:creator xml:lang="en">Shobha Pukale, Snehal Jarag, Vaishnavi Salokhe, Aarti Varne, Pratibha Adnaik, Omkar Yadav</dc:creator>
	<dc:subject xml:lang="en">Targeted drug delivery, cancer therapy, tissue engineering, Synthetic polymers</dc:subject>
	<dc:description xml:lang="en">Smart drug delivery system is an advanced method of drug targeted (dt) delivery. To enhance their therapeutic effects and reduce the related side effects, active drug molecules should selectively accumulate in the disease area for a prolonged period with high controllability. Targeted delivery requires special carrier systems. A tdd carrier is a special molecule, particle, composite, or system that has the ability to hold the drug in or on them, either by encapsulation and / or by means of a separator. Nano-carrier-based tdds have advantages such as higher surface-to-volume ratio, higher and more reactive activity centers, stronger adsorption capacity, and other properties such as morphological preferences. In this various type of targeted drug delivery system. Application of targeted drug delivery is used in diabetic patient, cancer therapy &amp;amp; tissue engineering.
The selection and design of a polymer are challenging tasks because of the inherent diversity of structures and require a thorough understanding of the surface and bulk properties of the polymer that can give the desired chemical, interfacial, mechanical, and biological functions. Natural polymers, e.g., gelatin, collagen, and lecithin, have been widely used in pharmaceuticals for many years. Synthetic polymers have gained a significant attention in recent years due to their wide range of varieties that offer added flexibility in terms of their application in ddss. These are available in a wide variety of composition with readily adjustable properties. Smart drug delivery system various manufacturing method, evaluation parameter can be monitored. In recent advances various marketed example used in targeted drug.</dc:description>
	<dc:publisher xml:lang="en">Sujata Publications</dc:publisher>
	<dc:date>2024-12-06</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://ijpdd.org/index.php/files/article/view/185</dc:identifier>
	<dc:identifier>10.62896/ijpdd.1.13.4</dc:identifier>
	<dc:source xml:lang="en">International Journal of Pharmaceutical Drug Design; IJPDD: Issue 13, Vol. 1, 2024; 21-29</dc:source>
	<dc:source>2584-2897</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/185/110</dc:relation>
	<dc:relation>https://ijpdd.org/index.php/files/article/view/185/118</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Sujata Publications</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc/4.0</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		<resumptionToken expirationDate="2026-05-22T19:10:36Z"
			completeListSize="233"
			cursor="0">8e855315175828c69ca1de8a8d93870c</resumptionToken>
	</ListRecords>
</OAI-PMH>
